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Abstract

DYNAMICS OF SUBSTRATE INTERACTIONS IN tRNA (m1G37)
METHYLTRANSFERASE: IMPLICATIONS FOR DRUG DISCOVERY
By Maria K. Palesis
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2012
Advisor: W. Michael Holmes, Ph.D.
Professor, Departments of Microbiology and Biochemistry

The bacterial enzyme t-RNA (m1G37) methyltransferase (TrmD) is an ideal antimicrobial drug target since it is found in all eubacteria, serves an essential role during protein
synthesis, and shares very little sequence or structural homology with its eukaryotic
counterpart, Trm5. TrmD, a homodimeric protein, methylates the G37 nucleotide of tRNA
using S-adenosyl-L-methionine (SAM) as the methyl donor and thus enables proper codonanticodon alignment during translation. The two deeply buried binding sites for SAM seen in
X-ray crystallography suggest that significant conformational changes must occur for
substrate binding and catalytic turnover. Results from molecular dynamics simulations
implicate a flexible loop region and a halo-like loop which may be gating the entrance to the
active site. Analysis of simulation trajectories indicates an alternating pattern of active site

xvii

accessibility between the two SAM binding sites, suggesting a single site mechanism for
enzyme activity. Isothermal titration calorimetry (ITC), demonstrates that binding of SAM to
TrmD is an exothermic reaction resulting from sequential binding at two sites. A similar mode
of binding at higher affinities was observed for the product, S-adenosyl-L-homocysteine
(SAH) suggesting that product inhibition may be important in vivo. ITC reveals that tRNA
binding is an endothermic reaction in which one tRNA molecule binds to one TrmD dimer.
This further supports the hypothesis of a single site mechanism for enzyme function.
However, mutational analysis using hybrid mutant proteins suggests that catalytic integrity
must be maintained in both active sites for maximum enzymatic efficiency. Mutations
impeding flexibility of the halo loop were particularly detrimental to enzyme activity.
Noncompetitive inhibition of TrmD was observed in the presence of bis-ANS, an extrinsic
fluorescent dye. In silico ligand docking of bis-ANS to TrmD suggests that dye interferes with
mobility of the flexible linker above the active site. Because SAM is a ubiquitous cofactor in
methyltransferase reactions, analogs of this ligand may not be suitable for drug development.
It is therefore important to investigate allosteric modes of inhibition. These experiments have
identified key, mobile structural elements in the TrmD enzyme important for activity, and
provide a basis for further research in the development of allosteric inhibitors for this enzyme.

xviii

Chapter 1
Introduction
1.1 tRNA (m1G37) Methyltransferase
tRNA modification enzymes play an important role in protein synthesis including
maintenance of tRNA tertiary structure and maintenance of proper contacts with proteins
and other RNA molecules. 1 In Escherichia coli, roughly 1% of the bacterial genome is
devoted to genes coding for RNA modification enzymes, 80% of which modify tRNA.6
(Figure 1a) This underscores their essential role in cellular function and viability.2, 3 One
very important modification enzyme is the m1G37 tRNA methyltransferase which
methylates the N1 group of guanine at position 37 of tRNA using S-adenosyl-Lmethionine (SAM) as the methyl donor. m1G37 tRNA methyltransferase is found in all
three domains of life, Eubacteria, Eukarya and Archaea, and is denoted TrmD, Trm5, and
aTrm5 respectively.6,45 (Figure 1b) This enzyme plays a critical role during the
translational phase of protein synthesis by maintaining proper codon:anticodon
alignment. Methylation of guanine at position 37, just 3’ of the anticodon nucleotides 34,
35, 36, provides a steric hindrance to further Watson-Crick base pairing between tRNA
and mRNA molecules. (Figure 2) This prevents the occurrence of frameshift mutations
that would otherwise lead to the formation of truncated or aberrant proteins.7,

8

The

essential role of this enzyme had been previously demonstrated in yeast and in Gram
negative bacteria.7, 9, 10 Recently, the Holmes Laboratory has shown that trmD expression
is also critical for growth and survival of Gram positive bacteria. By placing the trmD

1

(b)

(b)

(a)

Figure 1. tRNA nucleoside modifications.6 (a) Schematic representation of tRNA with
positions where a modified nucleoside has been found. Hypermodifications are noted for
position 34 (wobble) and position 37 (3’ adjacent of anticodon). The majority of this
information has been compiled from sequencing data of selected groups including Bacteria,
fungi, animals, chloroplasts, mitochondria, Archaea and Mollicutes. (b) Distribution of
hypermodified nucleosides at position 37. The m1G37 modification is found in all domains of
life.
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Figure 2. Effects of tRNA m1G37 methylation on Watson-Crick base pairing and codonanticodon alignment during protein translation. (a) Normal Watson-Crick base pairing
between guanine and cytosine. (b) m1G methylation (shown in red) impairs Watson-Crick
base pairing (c) tRNA m1G37 methylation on the anticodon loop promotes proper codonanticodon alignment during protein translation (left) while the absence of methylation is
conducive to frame shift alignments (center and right).

3

gene of Streptococcus pneumoniae under the control of an inducible p-fucose promoter, a
dose-dependent increase in growth rate was observed in bacterial cultures grown in
various concentrations of p-fucose.11 TrmD requires a G36pG37 consensus to methylate
the N1 group of guanine 37, thus only methylates tRNA species that recognize codons
starting with C which includes tRNALeu, tRNAPro and tRNAArg. Although in vitro studies
suggest that tRNA containing the A36pG37 consensus are also adequate substrates for
methylation by TrmD, no such naturally occurring m1G tRNA species have been isolated
from bacterial cells. tRNA species containing a pyrimidine base at position 36 are not
substrates of TrmD. 12-15
1.2 S-adenosyl-L-methionine dependent methyltransferases, classification and
structural motifs
The majority of SAM dependent methyltransferases, including Trm5, belong to
the Class I family which contains the canonical nucleoside pocket known as the
Rossmann fold. (Figure 3a) Substrates for Class I methyltransferases include RNA, DNA,
small molecules and other proteins. Most methyltransferases belonging to this group are
monomeric, although dimeric and tetrameric proteins have also been reported.16 TrmD
belongs to the Class IV or SPOUT family of SAM dependent methyltransferases which
contain a six stranded parallel β-sheet flanked by seven α-helices, of which the first three
strands form half of a Rossmann fold. (Figure 3b) In addition, they contain an unusual
α/β fold which forms a deep topological knot. (Figure 4) This knot, also referred to as a
trefoil knot, constitutes a major portion of the SAM binding pocket and is deeply buried
in the protein. All SPOUT methyltransferases identified thus far function as homodimers
and exclusively methylate only RNA
4

Figure 3. Schematic representation of S-adenosyl-L-methionine dependent
methyltransferases. (a) Class I SAM dependent methyltransferase cartoon depicting bound
SAM (AdoMet ) in Rossmann fold. (b) Class IV SAM dependent methyltransferase cartoon
depicting bound SAM in trefoil knot. Triangles and circles represent beta strands and alpha
helices, respectively.

5

Figure 4. Ribbon representation depicting the E. coli TrmD trefoil knot structure. One
half of the core beta sheet structure (yellow) of the protein is an integral part of the knot
structure. The SAH molecule is shown in licorice representation. Alpha helices are shown in
purple. The structures were generated using VMD. 114
(http://www.ks.uiuc.edu/Research/vmd).

6

substrates.17,18 Proteins belonging to Class I and Class IV methyltransferases can be
found in all three domains of life. 16, 19

1.3 TrmD crystal structure
The Holmes Laboratory was one of the first groups to solve the crystal structure
for TrmD, determining the Escherichia coli and Staphylococcus aureus structures at 2.5
Å and 2.6 Å resolution, respectively.20 Other solved TrmD structures include those of
Anaplasma phagocytophilum, Bartonella henselae, Haemophilus influenzae, and Aquifex
aeolicus.

21 22

All of the TrmD proteins share a remarkable sequence (Figure 5) and

structural homology. (Figure 6) Residues comprising the active site in the N-terminus and
residues surrounding the active site in the C-terminus are highly conserved. (Figure 7)
The E. coli TrmD homodimer is made up of two 30,500 Da monomers exhibiting an
antiparallel mode of dimerization.12

17

(Figure 8) Each monomer is made up of an N-

terminal domain linked to the C-terminus by a long unstructured loop for which electron
density is missing in the available crystal structures. The trefoil knot, which forms part of
the SAM binding site, resides on the N terminus at the interface of the two monomers.
The crystal structures obtained with bound SAM or SAH, appear to have two molecules
bound per protein.20, 22 The entrance to the deeply embedded SAM binding pocket for the
E. coli TrmD structure is “guarded” by a “halo” loop from one monomer and the residues
comprising an unstructured flexible linker (determined from loop homology modeling,
unpublished data) from the other monomer. This suggests that substantial enzyme
conformational changes must occur to allow movement of ligand into and out of the

7

Figure 5. Multiple sequence alignment of TrmD proteins from different bacterial
species.20 Multiple sequence alignment of TrmD was performed using ClustalW for the
following bacterial species: E. coli (NP_417098), H. influenzae (NP_438371), Streptococcus
pneumoniae (NP_358281), Synechocystis sp (BAA16843), Treponema pallidum
(AAC65860), Mycoplasma pneumoniae (AAB95831) and Aquifex aeolicus (AAC07418). The
degree of conservation is indicated by residue shading with highly conserved residues shaded
dark and less conserved residues shaded lighter or not at all. The secondary structure of
specific sequences is illustrated above the alignment. Many of the conserved residues
correspond to SAM binding regions or regions surrounding the SAM binding pocket.

8

Figure 6. Structural alignment of TrmD from different bacterial species: Anaplasma
phagocytophilum (royal blue, PDB ID: 3KNU), Bartonella henselae (cyan, PDB ID: 31EF),
Escherichia coli (green, PDB ID: 1P9P), Haemophilus influenzae (fuchsia, PDB ID: 1UAL),
Staphylococcus aureus (red, PDB ID: 3KY7 ) and Aquifex aeolicus (yellow, PDB ID: 1OY5).
The C- and N-terminal domains are depicted in ribbon diagrams. Residues comprising
unstructured loop regions (dotted lines) connecting the two domains were missing electron
density in all of the solved TrmD crystal structures. The structures represent a single
monomer of the homodimeric protein. The PDB files were obtained from the NCBI protein
sequence database. Structural alignment and molecular graphics images were produced using
the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco. 116 (supported by NIH P41 RR01081) http://www.cgl.ucsf.edu/chimera
9

Figure 7. Depiction of conserved residues in aligned TrmD crystal structures from
different bacterial species: Anaplasma phagocytophilum ( PDB ID: 3KNU), Bartonella
henselae (PDB ID: 31EF), Escherichia coli ( PDB ID: 1P9P) , Haemophilus influenza (PDB
ID: 1UAL), Staphylococcus aureus (PDB ID: 3KY7) and Aquifex aeolicus (PDB ID: 1OY5).
The ribbon representations of these structures correspond to residues from a single monomer
of the homodimeric protein. Highly conserved residue regions are shown in blue and cluster
around the SAM binding site in the N-terminus. Additionally, conserved residues can be seen
in the lower region of the C-terminal domain which correspond to residues above the active
site on the opposite side of the molecule. This is consistent with an anti-parallel mode of
dimerization. Residues on the far end of the C-terminus (shown in red) are not very conserved
in these bacterial species. The structural alignment and analysis was generated using VMD
MultiSeq 2.0. 113-115 (http://www.ks.uiuc.edu/Research/vmd)
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Figure 8. The TrmD homodimeric structure. The two monomers comprising the TrmD
protein (depicted in rose and cyan, ribbon representation above) are aligned in an anti-parallel
mode of dimerization. The two SAM ligands (shown in ball and stick representation) are
deeply buried in the interior of the molecule in binding sites comprised of residues from both
monomers. The entrance to each of the SAM binding pockets is “guarded” by a “halo” loop
from one monomer and a flexible linker from the other monomer. The residues comprising
the flexible linker were missing electron density in the crystal structure and were modeled in
using loop homology (Tripos® SYBYL 7.0). 77 The structures were generated using VMD. 114
(http://www.ks.uiuc.edu/Research/vmd)

11

catalytic center.

1.4 Mutational analysis of E. coli TrmD
Extensive mutational analysis was performed on the E. coli TrmD enzyme
ranging from C-terminal deletions to single residue mutations of conserved amino
acids.20 In general, the C-terminus is thought to play a role in tRNA binding since it is
characterized by an alpha helical bundle region known to contribute to nucleic acid
interactions. None of the single residue mutations, including many in the C-terminus, has
a measurable effect on tRNA binding. However, truncation of 60 residues from the Cterminus domain abolishes enzyme activity and tRNA binding. Truncation of 21 residues
from the C-terminus have little effect on enzyme activity. This region of the enzyme is
not strongly conserved among bacterial strains and therefore it is not surprising that
deletions have little effect. Mutations of many active site residues resulted in enzyme
inactivation most of which were not able to bind SAM. A few of these inactive mutants,
however, were able to bind SAM including R154A, R114A, and D169A.

Ionic

interactions from R114 appear to contribute to structural stability while R154 projects
into the active site with no apparent ionic interactions with other nearby residues. Given
that R154A can still bind both tRNA and SAM, and given its close proximity to the
active site, this suggests that a critical post binding event is diminished by this mutation
which could include a possible base-flipping role for R154. D169 resides in the
disordered loop connecting the C and N-terminus (Figure 9a) and has been hypothesized
to deprotonate N1G37 which proceeds to an SN2 methyltransferase reaction scheme
(Figure 9b). While mutation of D169 to alanine abolishes enzyme activity, mutation of
12
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Figure 9. Diagram showing the position of aspartate 169 in the E. coli TrmD structure
and its role during catalysis (a) Ribbon representation of TrmD with enlarged region
depicting Asp 169 as a stick figure above the active site and SAM in a space filled
representation at the interface between the two monomers. (b) An SN2 reaction scheme
modeling the deprotonation of N1 of G37 by Asp 169 The structures were generated using
VMD. 114 (http://www.ks.uiuc.edu/Research/vmd).
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D169 to another acidic amino acid, glutamate, restores activity. Other inactive mutants
were able to bind the product SAH, but not SAM, namely, G141A, Y136A, E186A.
1.5 tRNA binding and methylation
Efficient methylation of tRNA requires the full tRNA molecule, although
methylation is observed with compromised efficiency using only the core tRNA structure
(a canonical anticodon stem and loop structure with an acceptor stem).14 TrmD
methylates only tRNA species containing a G(A)36pG37 consensus. However, gel-shift
experiments using cognate and noncognate tRNA show that specificity is not determined
at the level of binding since both cognate and non-cognate species have similar Kd
values. Lead acetate cleavage assays of tRNA-bound TrmD show considerable protection
of the phosphodiester backbone in the anticodon loop. However, no protection is
observed for the G36pG37 backbone unless sinefungin, a non-reactive SAM analog, is
also bound to the protein. This suggests that movement of these two bases into the active
site only occurs if the methyl donor is already bound. This finding is corroborated by
FRET analysis using 2-aminopurine (2AP) substituted tRNA (36p37). 2-aminopurine is
a fluorescent analog of adenosine and guanosine that is commonly used to probe nucleic
acid structure and dynamics.23,24 As increased concentrations of sinefungin were added to
TrmD-2AP tRNA, the 36p37 bases moved further away from the single tryptophan
molecule, W201, thus decreasing energy transfer efficiency.25
1.6

Comparison of TrmD and Trm5
While both TrmD and Trm5 share the same cellular function, the N1 methylation

of G37 in tRNA, they differ in many ways.26 TrmD and Trm5 share very little sequence
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and structural homology.27 As pointed out previously, TrmD belongs to Class IV
methyltransferases which contain a deeply buried trefoil knot binding pockets for SAM,
while Trm5 belongs to Class I which contain a Rossmann fold motif for the binding of
SAM. Our laboratory has cloned the human Trm5 protein and reported on several key
aspects of methylation and substrate specificity.12 The TrmD protein functions as a
homodimer of 30,586 Da subunits and specifically requires a G(A)36pG37 motif on the
tRNA anticodon loop while Trm5 functions as 60,772 Da monomer without base
specificity requirements for position 36. TrmD also requires the presence of magnesium
ions for function while Trm5 lacks this requirement. TrmD does not have strict structural
requirements for tRNA methylation, i.e., it is capable of methylating tRNA species
lacking the T or D stem albeit at compromised efficiency. Trm5, however, is catalytically
inactive given the same tRNA species. Recently, an aTrm5–tRNA co-crystal from
Archeal M. jannaschii has been reported. It appears that aTrm5 interacts with the outer
corner of the L-shaped tRNA as well as with the anticodon loop, (Figure 10) and
experiments show that tRNA species lacking the proper L-shaped tertiary structure are
poor substrates for this enzyme. It is suggested that aTrm5 interactions with the outer
edge of the L-shaped tRNA act as a sensor for properly folded species and serve as a
“checkpoint” by preventing immature tRNAs (those lacking the modifications necessary
for proper L shape folding) from entering the translational stage. The differences in
homology, specificity and mode of action between TrmD and Trm5 make it possible to
develop selective inhibitors to the bacterial TrmD protein.28,29
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Figure 10. The structure of M. jannaschii aTrm5 in complex with tRNALeu: the three major
domains of aTrm5 D1, D2 and D3 are depicted in ribbon representation and shaded blue. The
backbone structure of tRNALeu is shown in gold. The D1 domain is thought to function as a
“checkpoint” sensor by making contact with the outer corner of the L-shaped tRNA structure
assuring proper fold. Mutations of the nucleotides contributing to base pairings in the L-shape
tertiary structure of tRNA abolish recognition of tRNA by aTrm5.29 The structures were
generated using the PDB file from aTrm5 (PDB ID: 2ZZN)28 and VMD. 114
(http://www.ks.uiuc.edu/Research/vmd)
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1.7 Pharmacological implications
Most of the drug classes currently in use as antibacterial agents were identified
within the first two decades following the discovery of penicillin by using empirical
screening techniques of natural product libraries.

30 31

Since then, development of new

antibiotics has focused on chemical modifications of these existing structural classes to
improve pharmacokinetic and pharmacodynamic properties as well as to circumvent
resistance mechanisms. Despite this strategy, chemical diversity has failed to keep up
with the pace of resistance to antibacterial drugs, underscoring the urgent need for the
development of new drugs in this arena. 32-34 In recent years, other approaches have been
introduced to identify novel drug targets for structurally distinct antimicrobial agents with
the rationale that these agents are likely to have different modes of action from existing
antibiotics and should therefore decrease the likelihood of cross resistance. 35-40 One such
targeted based approach is the genomic assessment of pathogenic bacteria for novel
broad-spectrum targets. This approach was fomented by the recent genomics revolution
and the wealth of knowledge now available on completely sequenced genomes.

41-45

A

recent study conducted by White et al. in the UK analyzed the genomes of
Staphylococcus aureus, Escherichia coli, and Mycobacterium tuberculosis, three
pathogenic bacteria representing a broad cross section of bacterial species. Through a
systematic BLAST query scheme, protein sequences found in these three genomes were
characterized and scored based on a number of attributes, with emphasis on those
contributing to essentiality and specificity to bacterial pathogens. Among the novel
protein targets that were identified by this study, the one with the highest ranking based
17

on these attributes was TrmD. 46 The essential role of this protein to bacterial growth and
survival has already been demonstrated by our laboratory and by others,

9 11

while the

lack of sequence and structural homology to the eukaryotic equivalent, Trm5, suggests a
promising potential for the development of highly specific antibacterial drugs.12
1.8 Focus of this dissertation
In order to explore high throughput alternatives for screening potential inhibitors
of TrmD, the enzyme was probed with bis-ANS (4,4'-bis-1-anilinonapthalene-8sulfonate), an extrinsic hydrophobic fluorescent dye. The binding of substrate molecules,
tRNALeu and SAM was assessed in the presence of bis-ANS. In addition, the effects on
enzyme activity of bis-ANS and two other extrinsic fluorescent dyes, congo red and
thioflavin T, were evaluated using an enzyme assay based on the radiolabeled substrate,
S-[methyl-3H]-adenosyl-L-methionine. Results of these studies are discussed in Chapter
2. To identify changes in protein dynamics as a result of cofactor binding, equilibrium
molecular dynamics simulations were performed for both SAM-bound and apo-TrmD
enzyme. Root mean square deviations per residue for Cα atom fluctuations during the
simulation were calculated, implicating highly flexible structural elements surrounding
the active sites. Additional findings suggested active site asymmetry between the two
catalytic centers. Results of molecular dynamics simulations are discussed in Chapter 3.
To address the proposed active site asymmetry, several experimental approaches were
implemented. Stoichiometry of binding was determined for SAM, SAH and tRNALeu
using Isothermal Titration Calorimetry (ITC). In addition, different types of homodimeric
and heterodimeric mutant TrmD proteins were constructed to evaluate structural
interdependence between the catalytic centers. Results of these studies are described in
18

Chapter 4. Finally, a short discussion follows chapter 4, highlighting salient conclusions
and future directions.
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Chapter 2
Effects of Extrinsic Fluorescent Dyes on TrmD Activity and Substrate Binding
2.1

Introduction
Our initial interest in probing the TrmD protein with fluorescent dyes was

generated by a need to explore changes in structure which might occur as a consequence
of ligand binding. Information gained from such studies would have great implications in
the development of high throughput alternatives for screening potential inhibitors of
TrmD. Four different extrinsic fluorescent dyes were used for these studies: ANS, bisANS, congo red, and thioflavin T. Substrate interaction and/or inhibitory effects of these
dyes were evaluated using recombinant TrmD protein from E. coli, M. tuberculosis, and
S. pneumoniae.
2.2

Extrinsic fluorescent dyes

2.2.1 ANS
The use of extrinsic fluorescence dyes have been used for years to study protein
folding and hydrophobic binding sites on the surface of proteins. 47 During the 1950’s, it
was discovered that several substituted aniline groups on naphthalene derivatives such as
ANS (1-anilinonaphthalene-8-sulfonate) (Figure 11a) became highly fluorescent when
placed in apolar organic solvents or upon adsorption to solid phases.

48

Subsequent

experiments explored dye protein interactions that included serum albumin quantitation
via fluorometric analysis, antibody characterization of dye-antibody complexes and
detection of Bence-Jones protein, a globulin protein found in serum or urine of multiple
20
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Figure -11. The chemical structures of (a) ANS (1-anilinonaphthalene-8-sulfonate) and (b)
bis-ANS, (4,4'-bis-1-anilinonaphthalene-8-sulfonate are depicted above.
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myeloma patients. 48 One of the first classic experiments using fluorescent dyes to probe
substrate binding site on a protein was conducted by Lubert Stryer in 1965 using ANS to
generate apomyoglobin and apohemoglobin dye complexes. Since the structure of
myoglobin had recently been solved using x-ray crystallography, the hydrophobic hemin
binding region of this protein was well characterized, which made it an ideal candidate
for probing with ANS. He observed that fluorescence was greatly increased when ANS
was bound to these proteins and yielding a stoichiometry of 1:1 for ANS-apomyoglobin
and 4:1 per ANS-apohemoglobin tetrameric molecule. Furthermore, it was observed that
fluorescence decreased with the addition of hemin suggesting that ANS and heme bind at
the same site. 48
2.2.2 Bis-ANS
The fluorescent dye bis-ANS, (4,4'-bis-1-anilinonaphthalene-8-sulfonate) (Figure
11b), the dimeric analogue of ANS, was discovered accidentally by Rosen and Weber in
the late 1960’s while probing bovine serum albumin (BSA) with ANS. 48 It was observed
that the fluorescence intensity of ANS bound BSA doubled in a period of 20 minutes.
After ruling out changes in protein conformation, it was concluded that chemical changes
in the dye must be responsible for the increased fluorescence. It was also deduced that
nitrous ions were required for ANS dimerization which were present in small amounts on
the walls of cuvettes that had been previously washed with nitric acid. Bis-ANS was later
synthesized from ANS by the addition of NaNO2 at low pH and it was noted that the
yield was much higher in the presence of BSA than without the addition of this protein.
Just as with ANS, bis-ANS has been a valuable tool for studying stages of protein folding
where the exposure of hydrophobic core pockets on proteins increase or decrease
22

depending on the degree of folding or unraveling. bis-ANS has also been used to study
surface hydrophobicity of proteins to elucidate chaperone binding sites and binding
partners. For some proteins, it was found that bis-ANS may actually act as a chaperone
by binding to hydrophobic patches on proteins to prevent chemical or thermally induced
aggregation.

49

Bis-ANS has also been used to probe the active site of proteins and has

been found to inhibit the activity of a number of enzymes. Of notable mention is the
extensive research with bis-ANS and tubulin. 50-52 Bis-ANS has been found to be a potent
inhibitor of microtubule assembly by binding to tubulin and making it more susceptible
to degradation. 53
Several naphthalene sulfonates including bis-ANS have been used to study
aggregation of the β-amyloid peptide which is believed to cause neurotoxicity leading to
Alzheimer’s disease.

54

It was found that the addition of these compounds to select β-

amyloid oligomers prevented the formation of aggregates in vitro, with bis-ANS having
the highest potency. Since aggregation of Aβ is thought to involve both hydrophobic and
electrostatic interactions, compounds like bis-ANS comprised of apolar aromatic rings
and negatively charged sulfonate groups may impede inter-peptide interactions by
binding to and shielding these contacts. However, bis-ANS is not able to bind to formed
fibrils.

55 54

Other fluorescent dyes, such as congo red and thioflavin T, are commonly

used to characterize amyloid fibril formation. 54 47
2.2.3 Congo red
Congo red (3,3'-([1,1'-biphenyl]-4,4'-diyl)bis(4-aminonaphthalene-1-sulfonic acid))
(Figure 12a) was synthesized in the late 1800 by Paul Bottiger.

56

It was first used as a

textile dye due to its strong binding to β-glucans such as cellulose. Medical applications
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Figure 12. The chemical structures of (a) Congo red (3,3'-([1,1'-biphenyl]-4,4'-diyl)bis(4aminonaphthalene-1-sulfonic acid)) and (b) Thioflavin T, 4-(3,6-dimethyl-1,3-benzothiazol3-ium-2-yl)-N,N-dimethylaniline chloride)) are depicted above.
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also take advantage of this characteristic where congo red is used to detect the presence
of bacteria which contain β-lactam in their cell walls. 57 In 1922, congo red was found to
bind strongly to amyloid protein by a German researcher, H. Bennhold, and has since
remained the gold standard for amyloid fibril analysis.

58 59

Like bis-ANS, congo red

possesses both polar and apolar groups enabling both hydrophobic and electrostatic
interactions. To date, there are no crystal structures available of congo red bound to either
protein or β-glucans, however in silico docking studies have been published for both.

60

Energetically favorable conformations of docking depict the dye in a planar
configuration. 61
2.2.4 Thioflavin T
Thioflavin T, 4-(3,6-dimethyl-1,3-benzothiazol-3-ium-2-yl)-N,N-dimethylaniline
chloride)), is a benzothiazole salt that has a hydrophobic component with a
dimethylamino group attached to a phenyl and a hydrophilic component with a
benzothiazole group containing the polar N and S (Figure 12b). This combination of
polar and non polar regions allows the molecule to form micelles in aqueous solutions,
and this characteristic is thought to underlie the mechanism by which it binds to amyloid
fibrils. Like congo red, thioflavin T is used extensively to detect amyloid structures.62
Given the general utility of these interesting compounds, we set out to determine
how they could be used to study the TrmD protein and the ligands with which it interacts.
2.3

Materials and Methods

2.3.1 Enzyme production and purification
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Data collected for the initial fluorescent probing was obtained using recombinant
TrmD protein derived from Escherichia coli cDNA whereas later inhibition studies also
included recombinant protein from Streptococcus pneumoniae and Mycobacterium
tuberculosis. All three proteins had been previously cloned and transformed into
appropriate expression competent cells. The E. coli trmD gene was cloned by a former
student in this laboratory, Maria Redlack, into a pET28 vector containing an N-terminal
hexahistidine tag and the kanamycin resistance gene. 20 63 The S. pneumoniae trmD gene
was originally cloned by Magdalena Zalacain of GlaxoSmithKline into a pET-15b vector
containing an N-terminal hexahistidine tag and the ampicillin resistance gene.11 The M.
tuberculosis trmD gene was cloned by Zohal Hamidi and Anuja Modi from Mtb gDNA
(strain H37Rv) into a pET-46 Ek/LIC vector containing a hexahistidine tag and the
ampicillin resistance gene.

64

The E. coli and S. pneumoniae trmD containing vectors

were transformed into BL21(DE3) competent expressions cells while the M. tuberculosis
trmD containing vector was transformed into Rosetta 2(DE3) cells.
The following protocol was used to purify large scale protein quantities for each
strain. A 30 mL Luria-Bertani (LB) broth starter culture containing appropriate
antibiotics was grown overnight at 37 °C in a rotary shaker (200 rpm). The starter culture
was used to inoculate one liter of LB broth which was then incubated under the same
conditions until an optical density (A600) between 0.6-0.8 absorbance units was attained at
which point the culture was induced for protein expression by the addition of 1 mM
isopropyl-β-D-thiogalactopyranoside (IPTG). After an overnight incubation at 18 °C
(225 rpm) the cells were harvested by centrifugation at 5,000 rpm for 10 minutes, resuspended in lysis buffer (50 mM sodium phosphate pH 7.5, 300 mM NaCl, 10 mM
26

imidazole) and passed twice through a French press at >20,000 psi. The homogenate was
centrifuged at 10,000 rpm for 20 minutes and the resulting supernatant containing the
desired soluble protein was added to a Ni+2-nitrilotriacetic acid (Ni-NTA) affinity column
(Qiagen). Wash buffer (50 mM sodium phosphate pH 7.5, 50 mM NaCl, 10 mM
imidazole) was added to the column to remove non-specific binding proteins. Elution of
TrmD protein was achieved using a sodium phosphate pH 7.5 buffer containing 250 mM
imidazole and 50 mM NaCl. Fractions with optical density (A280) greater than 0.5
absorbance units were pooled and dialyzed overnight in 4 liters of dialysis buffer (50 mM
sodium phosphate pH 7.5, 50 mM NaCl, 0.1 mM DTT and 10% glycerol) to remove the
imidazole. A typical yield consisted of 20-100 mg of protein per liter of culture. The
purity of recovered recombinant protein was assessed using 10% SDS-PAGE. (Figure 13)
The protein mixture was then stored at 4 °C until use.

2.3.2 tRNA synthesis and purification
pUTL4 plasmid purification
For all experiments presented in this dissertation, tRNA synthesis was achieved by
in vitro transcription of linearized pUTL4 plasmid containing E. coli tRNALeu cDNA
template. Three liter cultures of XL1-Blue cells containing the PUTL4 plasmid were
grown overnight in LB broth containing ampicillin. The cells were harvested by
centrifugation as described previously and plasmid was extracted using the Qiagen®
Plasmid Giga Kit™ (Qiagen) according to the manufacturer’s recommended protocol.
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Figure 13. Electrophoresis of recombinant TrmD proteins from M. tuberculosis, E. coli
and S. pneumoniae. 10% SDS-PAGE electrophoresis gels stained with coomassie blue show
TrmD samples from three different bacterial species. The bands on the first gel correspond to
M. tuberculosis TrmD while the band on the far left side of the second gel corresponds to E.
coli TrmD. The subsequent lanes on the same gel show electrophoresed samples from the
purification of S. pneumoniae TrmD. W1 to W4 and E1 and E2 are wash and elution samples,
respectively, from the Ni-NTA chromatography column. The samples were electrophoresed in
Tris-glycine buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) for 45 minutes at 150 V.
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A typical yield consisted of 1-3 mg of plasmid per liter of culture of which 10% was the
template for tRNALeu. The plasmid was then linearized using BstN I from New England
Biolabs® at a concentration ratio of 2,000 U of restriction enzyme per 1 mg of plasmid.
Following a 12 hour incubation at 60 °C, the digestion efficiency of BstN I was assessed
using a 1.5% agarose gel stained with ethidium bromide. (Figure 14) The DNA was
removed from the digestion mixture by a triplicate phenol (pH 8) chloroform/isoamyl
alcohol (25:24:1) extraction and precipitated by the addition of three volumes of 100%
EtOH, and 1/10 volume of 3 M sodium acetate (pH 5.2) followed by one hour
centrifugation at 12,000 × g. The DNA pellet was then air-dried for 30 minutes, resuspended in nuclease-free water (Quality Biological Inc.) and stored at -20 °C.
T7 RNA polymerase expression
Recombinant His-tagged T7 RNA polymerase (T7RNAP) required in the
transcription reaction was produced in large quantities and purified using Ni-NTA
affinity column in the same manner described previously for TrmD protein with the
following variations in buffer composition: Lysis buffer (50 mM sodium phosphate pH
8.0, 300 mM NaCl, 10mM imidazole), wash buffer (50 mM sodium phosphate pH 8.0, 50
mM NaCl, 10 mM imidazole), elution buffer (50 mM sodium phosphate pH 8.0, 50 mM
NaCl, 250 mM imidazole), and dialysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl,
1 mM DTT, 10% glycerol). Following dialysis, the protein was concentrated to
approximately 40 mg/ml using 10,000 MW cut-off Amicon® centrifugal filtration and
stored at -20 °C in 50% glycerol and 5 mM DTT.
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Figure 14. Electrophoresis gel of pUTL4 plasmid. Agarose gel (1.5%) stained with
ethidium bromide, showing intact pUTL4 plasmid (left lane) and after digestion with the
restriction endonuclease, BstN I (right lane). The pUTL4 plasmid which encodes tRNALeu,
contains a BstN I restriction site at the 3’ CCA end of the tRNA cDNA template. This results
in a tRNA run-off transcript during in vitro transcription with T7 RNA polymerase. The
samples were electrophoresed in 0.5 × TBE buffer for 30 minutes at 90 V.
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In vitro transcription
Prior to the setup of a large scale in vitro transcription reaction, a smaller reaction
volume totaling 1 mL was prepared to assess the efficacy of T7RNAP. The transcription
reaction mixture consisted of 50 mM Tris-HCl pH 8.1, 30 mM MgCl2, 1 mM spermidine,
5 mM DTT, 0.1% Triton X 100, 50 µl (40 mg/ml) of T7RNAP, 12 mM each of
neutralized rATP, rGTP, rCTP, UTP, and 100 µg of DNA template. Successful
transcription was assumed if a cloudy reaction mixture from MgPPi precipitation was
observed within an hour of a 37 °C incubation period. A larger scale reaction mixture of
about 25 mL was then set up and allowed to incubate until all the MgPPi had precipitated
and the solution was no longer cloudy. Usually this took about three hours. The reaction
mixture was then centrifuged for 10 minutes at 10,000 × g and the supernatant was
collected. A double phenol (pH 4-5) chloroform/isoamyl alcohol (125:24:1) extraction
and a single chloroform/isoamyl alcohol (24:1) extraction was performed to remove
template DNA and T7RNAP. The nucleic acid was then precipitated by the addition of 1
volume of 100% isopropanol, and 1/10 volume of 3 M sodium acetate (pH 5.2) followed
by one hour centrifugation at 12,000 × g. The pellet was washed with 70% EtOH, airdried for 30 minutes, and re-suspended in 0.1 M NaCl nuclease-free water solution. In
order to separate RNA from unincorporated rNTP’s and any remaining template DNA
that was not removed by the acid phenol extraction, the re-suspended RNA mixture was
added to 5 ml of a DEAE Sepharose weak-anion exchange column pre-equilibrated with
0.1 M NaCl. The column was washed several times with 0.1 M NaCl to remove
unincorporated rNTP’s. Elution of tRNALeu was achieved with 0.4 M NaCl leaving
behind any remnants of template DNA still bound to the column. The RNA was once
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again phenol/chloroform extracted and EtOH pelleted as described previously. The
quality of the tRNA product was assessed on a 10% PAGE, 8 M Urea gel. (Figure 15)
tRNA was stored in a small volume of nuclease free water at -20 °C.

2.3.3 Fluorescence studies
E. coli TrmD protein, prepared as previously described, was used for all
fluorescence studies. Previous experiments performed in this laboratory established that
both ANS and bis-ANS were able to bind to TrmD with bis-ANS resulting in
significantly higher quantum yields (unpublished results). For this reason, bis-ANS was
chosen to probe the enzyme in the presence and absence of substrate. Samples containing
1 µM bis-ANS, 1 µM TrmD, and either variable concentrations of SAM (25 µM, 50 µM,
75 µM), or variable concentrations of tRNA (5 µM, 10 µM, 15 µM) were prepared in
buffer (100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM MgCl2,, 0.1 mM EDTA, 1 mM
DTT). In addition, samples containing both substrates (25, 50, or 75 µM SAM paired
with 5, 10, 15, µM tRNA, respectively) along with enzyme and bis-ANS were also
prepared. Control samples prepared in the same buffer included substrates alone, enzyme
alone, bis-ANS alone, bis-ANS plus substrate alone, and bis-ANS plus enzyme alone.
Relative fluorescence was measured using a spectrofluorometer set at excitation and
emission wavelengths of 395 nm and 505 nm respectively. The mean relative
fluorescence, standard deviation and variance were calculated for each group set. In
addition, student t-Test at 95% confidence interval was calculated to evaluate
significantly different mean values between bis-ANS alone and bis-ANS bound to
32
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Figure 15 Electrophoresis of tRNA. A 10% PAGE, 8 M Urea gel stained with ethidium
bromide showing newly synthesized tRNA samples (center and right bands) and a reference
tRNA sample from previous experiments (left band). The samples were electrophoresed in 0.5×
TBE buffer for 40 minutes at 110 V.
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protein, bis-ANS bound to SAM and bis-ANS bound to tRNA. The student t-Tests (95%
confidence interval) was also calculated to evaluate significantly different mean values
between the bis-ANS bound TrmD samples and bis-ANS plus substrate bound TrmD
samples. All experiments were done in triplicate.

2.3.4 In vitro enzyme assay
A radiolabeled enzyme assay incorporating S-[methyl-3H]-adenosyl-L-methionine
(3H-SAM) was used to determine relative activity of TrmD enzyme. A total reaction
volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM MgCl2,
1.2µg Bovine Serum Albumin (BSA), 0.1mM EDTA, 1 mM DTT, 40 µM cold SAM, 1
µl (1.8 µCi) 3H-SAM (specific activity 10 Ci /mMol), 20 µM tRNALeu and optimized
amounts of strain specific enzyme (500 nM E. coli TrmD, 1.2 µM S. pneumoniae, TrmD,
7.1 mM M. tuberculosis TrmD). Samples were prepared as described above without
enzyme and allowed to incubate for 10 minutes at 37 °C to pre-warm reaction mixture.
The enzyme reaction was initiated by the addition of TrmD and incubation was continued
for 4 minutes at 37 °C. Forty µl aliquots from each sample were then added to DE81
Whatman filter paper, washed twice with ice-cold 5% trichloroacetic acid (TCA), and
rinsed with 100% ethanol. Filter papers were air-dried for at least 45 minutes, placed into
vials containing 5 mL ScintiLeneTM SX2-4 scintillation cocktail (Fisher Scientific) and
counted on a Beckman Coulter LS 6500 Scintillation counter. Two types of negative
control samples were assayed for each run, one excluding isotope and one excluding
enzyme.
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For experiments comparing the inhibitory effects of bis-ANS, congo red and
thioflavin T, the ligand concentration used was 156 µM. Enzyme and substrate
concentrations were as described above. For Ki determination of bis-ANS with respects
to tRNA, concentrations of bis-ANS and tRNA were 0.0, 7.2, 14.4, 21.6, and 18.0, 9.0,
4.5, 2.25, 1.12 µM, respectively. The enzyme, 3H-SAM and cold SAM concentrations
were as described above. For Ki determination of congo red with respect to SAM, the
concentrations of congo red and SAM were 0.0, 1.1, 2.2, 4.4, and 5, 10, 15, 20 µM,
respectively. The enzyme, and tRNA concentrations were as described above. The ratio
of 3H-SAM to cold SAM was held constant for all concentrations of SAM used. The data
was analyzed using nonlinear regression with the software GraphPad Prism for the
determination of Ki values.

2.4

Results and Discussion of Fluorescence Studies
Relative fluorescence values were obtained in order to assess the effects of bis-

ANS binding to TrmD enzyme in the presence and absence of substrate. It was
hypothesized that if the substrate bound at the same place on the enzyme as the dye, then
it would displace the dye, decreasing fluorescence. Several control values were obtained
in order to establish baseline fluorescence for TrmD, bis-ANS, bis-ANS bound to TrmD,
SAM, bis-ANS bound to SAM, tRNA and bis-ANS bound to tRNA. Standard t-test
analysis at 95% confidence interval was used to evaluate significantly different means
between bis-ANS alone and bis-ANS bound to protein, bis-ANS bound to SAM and bisANS bound to tRNA. There was an obvious significant increase when bis-ANS was
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bound to protein. (Figure 16) There was also slight increase in fluorescence when bisANS was bound to tRNA which was significant compared to the fluorescence of bisANS alone. There were no significant differences between bis-ANS and bis-ANS bound
to SAM.
Standard t-test analysis at 95% confidence interval was also used to evaluate
significant differences in the means of bis-ANS bound to TrmD alone vs various
concentrations of added substrate. (Figure 17) Of all the groups evaluated, only one
group yielded significantly different mean values. When comparing the highest
concentration of added substrates (mixture of both SAM and t-RNA) it had a
significantly higher mean than that of bis-ANS bound to TrmD alone.
None of the bis-ANS bound TrmD samples decreased in fluorescence with the
addition of substrate molecules. This suggests that bis-ANS binds to enzyme at a site
different from the binding site of tRNA or SAM. The fact that there was a trend for
increased fluorescence with the presence of tRNA in the bis-ANS bound TrmD samples
suggests a couple of possibilities. It may be that the binding of tRNA induces a
conformational change in the protein burying the dye even further in a hydrophobic
pocket which would result in increased fluorescence. It could also be possible that the
dye binds to tRNA in addition to the protein which would agree with the increased
fluorescence observed for the baseline result of bis-ANS bound to tRNA. This is also
consistent with the literature of bis-ANS binding to nucleic acids.
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Figure 16. Baseline relative fluorescence measurements for bis-ANS, TrmD, SAM, and
tRNA. Fluorescence intensities were measured in samples containing TrmD, SAM or tRNA
before and after addition of bis-ANS and were compared to fluorescence intensities from
control samples containing only bis-ANS. A marked significant increase was noted when bisANS was added to protein. A significant increase was also noted when bis-ANS was added to
tRNA. Samples were prepared in 100 mM Tris-HCl, pH 8.0 buffer. The concentrations of bisANS, SAM, tRNA and TrmD were 0.1 µM, 75 µΜ, 15 µΜ and 1.0 µΜ, respectively.

Experiments were conducted using an excitation wavelength of 395 nm and an
emission wavelength of 595 nm. A student t-test analysis ( 95% confidence interval)
was used to evaluate significant differences in mean fluorescence values. All
experiments were done in triplicate.
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Figure 17. Relative fluorescence of bis-ANS bound TrmD after addition of substrate.
Fluorescence intensities were measured in samples containing bis-ANS-bound TrmD after
addition of variable concentrations of SAM (25 µM, 50 µM, 75 µM), tRNA (5 µM, 10 µM,
15 µM), or a combination of both substrates (25, 50, or 75 µM SAM paired with 5, 10, 15,
µM tRNA, respectively). The fluorescence of each substrate group was compared to that of
bis-ANS bound TrmD. The legend on the left indicates the sample groups represented on the
graph above. None of the bis-ANS bound TrmD samples decreased in fluorescence with the
addition of substrate molecules. This suggests that bis-ANS binds to enzyme at a site different
from that of tRNA or SAM. However there was a significant increase noted in one of the
groups containing both substrates which may indicate a perturbation in protein structure
resulting in a more optimized hydrophobic pocket for bis-ANS. Samples were prepared in
100 mM Tris-HCl, pH 8.0 buffer. The concentrations of bis-ANS, and TrmD were each 0.1
µM and the variable concentrations of each substrate group were as described above.
Experiments were conducted using an excitation wavelength of 395 nm and an emission
wavelength of 595 nm. A student t-test analysis (95% confidence interval) was used to
evaluate significant differences in mean fluorescence values. All experiments were done in
triplicate.
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2.5

Results and discussion of inhibitor studies

2.5.1 Initial inhibitor screening
Three species of bacterial TrmD proteins, E. coli, S. pneumoniae, and M.
tuberculosis, were assayed in the presence of extrinsic fluorescent dyes. (Figures 18, 19,
20) All proteins showed reduced activity under 156 µM concentrations of bis-ANS and
congo red. The activities of E. coli, and S. pneumoniae were not affected in the presence
of thioflavin T. The TrmD enzyme from M. tuberculosis was not tested for activity in the
presence of thioflavin T. In addition, both bis-ANS and it’s monomeric analog ANS were
tested for inhibitory effects on E. coli TrmD since previous studies in our laboratory
determined that both ANS and bis-ANS produced a robust fluorescent signal upon
binding. Surprisingly, ANS had no effect on enzyme activity. (Figure 21) It is interesting
to note the differences in structure composition of the compounds. (Figures 11 and 12)
The fluorescent dyes that are able to inhibit enzyme activity, bis-ANS and congo red
have a dimeric symmetry. In silico docking of bis-ANS to TrmD performed by Dr.
Alexander Bayden using GOLD docking program and HINT scoring function, depict the
compound intercalated into the flexible linker in a twisted conformation about the diphenyl bond. (Figures 22a and 22b)

65-67

This intercalation may interfere with the

dynamics of the flexible region which contains the catalytic residue D169, discussed
previously, and thus compromises enzyme function.
2.5.2 Ki determination for bis-ANS and congo red
A Ki value of 11.3 ± 1.7 µM was determined for bis-ANS using non-linear
regression (Figure 23a and 23b). The data was fitted to a noncompetitive binding model.
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Figure 18. Enzyme activity of E. coli TrmD in the presence of bis-ANS, congo red and
thioflavin T. In vitro methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-Lmethionine was used to measure TrmD activity in the presence of three fluorescent dyes, bisANS, congo red and thioflavin T. Activity is reported as percent of control (TrmD activity in
the absence of dye). Both bis-ANS and congo red substantially reduce enzyme activity while
thioflavin T has no effect. A total reaction volume of 50 µl consisted of 100 mM Tris-HCl pH
8.0, 24 mM NH4Cl, 6 mM MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold
SAM, 1 µl (1.8 µCi) 3H-SAM (specific activity 10 Ci /mMol), 20 µM tRNALeu, 500 nM E.
coli TrmD and 156 µM of dye. All experiments were done in triplicate.
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Figure 19. Enzyme activity of M. tuberculosis TrmD in the presence of bis-ANS, and
congo red. In vitro methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-Lmethionine was used to measure TrmD activity in the presence of two fluorescent dyes, bisANS and congo red. Activity is reported as percent of control (TrmD activity in the absence
of dye). Both bis-ANS and congo red substantially reduce enzyme activity with congo red
having a more potent effect. A total reaction volume of 50 µl consisted of 100 mM Tris-HCl
pH 8.0, 24 mM NH4Cl, 6 mM MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold
SAM, 1 µl (1.8 µCi) 3H-SAM (specific activity 10 Ci /mMol), 20 µM tRNALeu, 500 nM M.
tuberculosis TrmD and 156 µM of dye. All experiments were done in triplicate.
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Figure 20. Enzyme activity of S. pneumoniae TrmD in the presence of bis-ANS, and
congo red. In vitro methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-Lmethionine was used to measure TrmD activity in the presence of two fluorescent dyes, bisANS and congo red. Activity is reported as percent of control (TrmD activity in the absence
of dye). Both bis-ANS and congo red are equally potent in reducing enzyme activity. A total
reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM
MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM
(specific activity 10 Ci /mMol), 20 µM tRNALeu, 500 nM S. pneumoniae TrmD and 156 µM
of dye. All experiments were done in triplicate.
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Figure 21. Enzyme activity of E. coli TrmD in the presence of ANS and bis-ANS. In vitro
methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-L-methionine was used to
measure TrmD activity in the presence of two fluorescent dyes, ANS and bis-ANS. Activity is
reported as percent of control (TrmD activity in the absence of dye). ANS has no effect on
enzyme activity while bis-ANS, a dimeric version of ANS, substantial reduces enzyme
activity. A total reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM
NH4Cl, 6 mM MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold SAM, 1 µl (1.8
µCi) 3H-SAM (specific activity 10 Ci /mMol), 20 µM tRNALeu, 500 nM TrmD and 156 µM
of dye. All experiments were done in triplicate.
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(a)

(b)

Figure 22. A structural model of E. coli TrmD in complex with docked bis-ANS. (a) The
homodimeric tertiary structure of E. coli TrmD is shown as ribbon representation with docked
bis-ANS depicted as ball and stick figure. The two SAM ligands are modeled as vdW space
filled figures. (b) Three bis-ANS ligands, representing energetically favorable conformations,
are shown intercalated between the flexible linker above the active site. Bis-ANS binding was
modeled using GOLD ligand-docking software and energetically favorable conformations of
protein-bound ligand, were scored using HINT algorithms. 65-67 The in silico binding studies
were conducted by Dr. Alexander Bayden, a post-doctoral fellow in the laboratory of Dr. Glen
Kellogg, VCU Medicinal Chemistry department. The structures of bis-ANS and TrmD were
generated using VMD. 114 (http://www.ks.uiuc.edu/Research/vmd).
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Figure 23. Ki determination for Bis-ANS (a) In vitro methylation of tRNALeu, incorporating
S-[methyl-3H]-adenosyl-L-methionine was used to measure TrmD activity with titrated
concentrations of bis-ANS (0.0, 7.2, 14.4 and 21.6 µM ) and tRNA (1.12, 2.25, 4.5, 9.0, 18.1
µM). (b) Non-linear fit to a noncompetitive model yielded a Ki value of 11.3 ± 1.7 µM for
bis-ANS. (c) The data was also analyzed using Lineweaver–Burk double-reciprocal plots
which reveal a similar Kmobs and variable Vmax obs. consistent with noncompetitive binding. A
total reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM
MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM
(specific activity 10 Ci /mMol), variable concentrations of µM tRNALeu, 500 nM TrmD and
variable concentrations of bis-ANS. All experiments were done in triplicate. Nonlinear
regression was performed using the GraphPad Prism software.
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Attempts to fit the data to other binding models, including competitive inhibition, mixed
inhibition, and uncompetitive inhibition yielded ambiguous results. The data was also
plotted using Lineweaver–Burk double-reciprocal plots which reveal a similar Kmobs and
variable Vmax obs. .(Figure 23c) This is consistent with a noncompetitive binding model. It
also corroborates the results obtained from fluorescent studies in which the relative
fluorescence of bis-ANS was not compromised with the additions of substrate. Bis-ANS
must therefore bind to a different site on the enzyme than that of tRNA binding.
The Ki for congo red was calculated using non-linear regression, however it was
not possible to determine the binding mode. Based on the raw data results (Figure 24a),
the highest concentration of congo red (4.43 µM) substantially decreased enzyme activity
compared to activity in the presence of half the amount of congo red (2.22 µM ). This
may be an indication of very tight binding resulting in irreversible inhibition. which
makes it difficult to ascertain the binding mode.

With the exception of the

‘uncompetitive inhibition’ model (Figure 34b) which could not be fitted to the data, the
competitive (Figure 34c), mixed (Figure 34d) , and noncompetitive (Figure 34e) models
yielded Ki values of 1.3 ± 0.3 µM, 1.8 ± 1.2 µM and 1.7 ± 0.3 µM, respectively. The
data was also plotted using Lineweaver–Burk double-reciprocal plots but it was not
helpful in deciphering a binding mode. (Figure 34f)
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Figure 24. Ki determination for congo red. (a) In vitro methylation of tRNALeu,
incorporating S-[methyl-3H]-adenosyl-L-methionine was used to measure TrmD activity with
titrated concentrations of congo red (0.0, 1.10, 2.22 and 4.43 µM ) and SAM (5, 10, 15 and 20
µM). The highest concentration of congo red (4.43 µM) substantially decreased enzyme
activity compared to activity in the presence of half the amount of congo red (2.22 µM ). This
may be an indication of very tight binding resulting in irreversible inhibition. which makes it
difficult to ascertain the binding mode (b) Data fitted to the ‘uncompetitive inhibition’ model
resulted in ambiguous Ki results. (c) Data fitted to the ‘competitive inhibition’ model gave a
Ki value for congo red of 1.3 ± 0.3 µM. (d) Data fitted to the ‘mixed inhibition’ model gave a
Ki value for congo red of 1.8 ± 1.2 µM (e) Data fitted to the ‘mixed inhibition’ model gave a
Ki value for congo red of 1.7 ± 0.3 µM. (f) data was also plotted using Lineweaver–Burk
double-reciprocal plots but it was not helpful in deciphering a binding mode. A total reaction
volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM MgCl2, 1.2 µg
BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM (specific
activity 10 Ci /mMol), variable concentrations of µM tRNALeu, 500 nM TrmD and variable
concentrations of bis-ANS. All experiments were done in duplicate. Non-linear regression
was performed using the GraphPad Prism software.
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Chapter 3
Analysis of Ligand Bound TrmD and Apo Enzyme Using Molecular Dynamics
Simulations

3.1

Introduction
X-ray crystallography of the eubacterial TrmD enzyme co-crystallized with ligand

reveal two binding sites for SAM which are deeply buried within the interior of the
enzyme. The cofactor-binding site is buried at one end of the N-terminal catalytic domain
in the interface between the N and C-terminal domains. An analysis of the structure
suggests that significant conformational changes must occur for substrate binding and
catalytic turnover. In order to identify changes in protein dynamics as a result of cofactor
binding, equilibrium molecular dynamics simulations were performed for both SAM
bound and the apo-TrmD enzyme. In this chapter, the theory and brief history of
molecular dynamics simulations will be introduced, followed by results and discussion of
simulation data for TrmD enzyme.

3.2

Introduction to molecular dynamics simulations
The computational method of molecular dynamics simulations (MD) is a major

tool in the theoretical study of biological molecules. It enables calculation of the time
dependent behavior of a molecular system. MD simulations have provided a wealth of
information of atomistic behavior resulting from fluctuations in conformational changes

48

and are now routinely used to investigate the structure, dynamics and thermodynamics of
biological molecules and their complexes.
3.3

History of molecular dynamics
The method of molecular dynamics was first introduced by Alder and Wainwright

in the late 1950's to study the liquid-solid phase transition of hard spheres.

68

In 1964,

Rahman carried out the first MD simulation using the Lenard-Jones energy potential of
liquid argon and in 1974, along with Stillinger, he carried out the first realistic simulation
of liquid water. 69 70 McCammon et al. carried out the first protein simulations in 1977 to
study protein folding of bovine pancreatic trypsin inhibitor (BPTI) in vacuum.71

72

With

advances in computer technologies that followed, more sophisticated computational
algorithms have been developed that now enable MD simulations of explicitly solvated
macromolecules such as proteins and nucleic acids as well as lipid bilayer systems.

3.4

Theory of molecular dynamics simulation method

3.4.1 Newton’s second law for the equation of motion
The molecular dynamics simulation method is based on Newton’s second law for
the equation of motion,

where F is the force exerted on the particle, m is its mass and a is its acceleration. The
force is also equal to the negative gradient of the potential energy (U), or
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Since it is possible to determine the potential energy and thus the force of a molecule at
an atomistic level, its path through space can be simulated. 73 74

The relative potential energy of a given particle is a sumation of all its bonded and nonbonded potential energy forces:

3.4.2 Bonded Potential Energy
Ubonded is the potential energy describing the bonds, angles and bond rotations in a
molecule and is the sum of three terms:

U

non-bonded

is the potential energy which accounts for interactions between non-

bonded atoms or atoms separated by three or more covalent bonds. It is the sum of the
following two terms:

The bonded and non-bonded potential energy terms are described in more detail
using the figure below.
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Bond length potential energy
The bonded length potential controls the length of covalent bonds. The most
commonly used form for bond-length potential is based on Hook’s law (harmonic
potential). In this case,

where rjk is the distance between covalently bonded atoms j and k, req is the
corresponding equilibrium distance, and krjk is the spring constant. The equilibrium
distance between atoms can be obtained from X-ray diffraction experiments or using ab
initio quantum calculations. The spring constant can be determined using the results of
infrared absorption and Raman spectroscopy.

Bond angle potential energy
The bond angle potential is designed to reproduce the bond geometry in
molecules, which in turn is controlled by the hybridization state of atomic orbitals. For
example, sp hybridization allows the formation of two bonds with the angle between
them of 180°. The sp2 or sp3 hybridization states result in trigonal or tetrahedral
arrangements of covalent bonds around the atom with bond angles of 120° or 109.5°,
respectively. It is also important to note that local environment may distort the bond
angles. For example, the oxygen in a water molecule, arranged in an sp3 hybridization,
has a bond angle of about 105°. From these parameters, the bond angle potential can be
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determined by again using the harmonic potential equation

where θ jkl is the angle resulting from the bonding geometry of particles j, k and l. θ eq is
the equilibrium angle and kθ

jkl

is the angle constant attributed to partilcles j, k and l.

Constants and equilibrium values can be obtained from experimental as well as ab initio
quantum calculations.

Dihedral bond potential energy
The third term comprising the bonded potential is the dihedral potential which
models the presence of steric barriers between atoms separated by 3 covalent bonds. It is
determined from the torsion angle between two planes containing the four consecutively
bonded atoms. This potential is periodic and is expressed as the cosine function

where kφ is the barrier height constant for consecutively bonded particles i, j, k, and l, n is
the integer which determines the periodicity of the potential (number of minima/maxima)
in the interval [0,2π], φ ijkl is the torsion angle between the two planes containing
consecutively bonded particles i, j, k, and l, and φ eq is the equilibrium torsion angle.
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3.4.3 Non-Bonded Potential Energy
Van der Waals interactions
The first energy term representing the contribution of non-bonded interactions is
the Van der Waals interaction energy which arises from a balance between repulsive and
attractive forces. All atoms exhibit a long range attraction which is proportional to R -6.
This is generally referred to as van der Waals (vdW) attraction. At suficiently short
distances, however, the interactions of all atoms are repulsive. The Lennard-Jones
potential equation shown below is one way to describe the Van der Waals forces and was
proposed by John Lennard Jones in 1924:

where r is the distance between particle i and j, ε is the depth of the potential well or the
equillibrium energy between particle i and j where repulsive forces are equal to the
attractive forces between these two particles, and σ is the shortest distance between i and
j resulting in zero potential energy.

Electrostatic interactions
The second term contributing to the non-bonded potential energy is the
electrostatic potential which accounts for the potential energy associated with charge
distribution. Typically, the electrostatic interaction dominates the total energy of a
system. It is a function of the charge on the non-bonded atoms, their inter atomic
distance, and a molecular dielectric expression that accounts for the decrease of
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electrostatic interaction due to the environment. The electrostatic contribution is modeled
using a Coulombic potential,

where qi and qj are the net atomic charges of atoms i and j respectively, r is the
interatomic distance between i and j , and ε 0 is the permitivity constant of the medium
between the interacting charges. The accuracy of the electrostatic term depends on the
correct assignment of charges to individual atoms which could be challenging since
experimental data of charges for molecules at atomic resolutions does not exist. There is
an ongoing effort in the molecular modeling community to develop better algorithms for
modeling ambient electric field effects of biomolecules.
3.4.4 Summary
In summary, the total relative energy of a particle is equal to the summation of all
potential energy tems described by the bonded and non-bonded equations

⎡⎛ σ ⎞ 12 ⎛ σ ⎞ 6 ⎤
qi ⋅q j
∑ 4ε ij ⎢⎜⎝ r ⎟⎠ − ⎜⎝ r ⎟⎠ ⎥ + ∑ 4πε
0r
⎢⎣
⎥⎦
The mathematical functions and associated constants used to describe potential
energy for each type of atom are also refered to as

‘force field parameters’. As

mentioned previously, these parameters are obtained from both experimental as well as
quantum mechanical calculations. A number of force field parameters such as
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CHARMM, AMBER, GROMOS as well as many others have been developed to model
macromolecules including proteins, nucleic acids, and lipid membranes.

75

From a

knowledge of the force on each atom (i), as determined from the negative gradient of
total potential energy,

it is possible to determine the acceleration of each atom in the system:

Integration of the equations of motion then yields a trajectory that describes the
positions, velocities and accelerations of the particles as they vary with time.76 Initial
positions of atomic coordinates can be obtained from x-ray crystalography or NMR
spectroscopy. Initial velocities are coupled to the temperature using the MaxwellBoltzman distribution. From this trajectory, the average values of properties can be
determined. The method is deterministic; once the positions and velocities of each atom
are known, the state of the system can be predicted at any time in the future or the past.

3.5

Methods for molecular dynamics simulations of TrmD
Preparation of protein for molecular dynamics simulations required several steps.

First, the pdb file, (1P9P), obtained from x-ray crystallography of E. coli TrmD, was
refined using Tripos SYBYL 7.0 software to build missing residues based on homology
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models of existing residue sequences.

77

In addition, all water molecules originally

present in the crystal structure were removed. The pdb file was then split into three
separate pdb files, one for each of the two monomers and a separate file for SAM. All
three pdb files were analyzed using the pdb2pqr program to assign appropriate
protonation states to each residue sidechain.

78-80

The monomers and ligand were

recombined using the program psfgen to create a new pdb file as well as a corresponding
protein structure file (psf). The protein was then solvated with TIP3P explicit water to
create a water box with a minimum of 15 angstroms from the largest atomic coordinate.
Enough Na+ and Cl- ions were then added to form a neutral system. (Figure 25)
Simulations were carried out using periodic boundary conditions to eliminate
surface effects. This was achieved by defining a space filling cell surrounded by identical
images of itself on all sides. Thus, atoms exiting one side of the solvent box could reenter from the opposite side. 81 The program NAMD 2.7, incorporating CHARMM force
field parameters and Langevin dynamics, was used to generate simulation trajectories.
NAMD was developed by the Theoretical and Computational Biophysics Group in the
Beckman Institute for Advanced Science and Technology at the University of Illinois at
Urbana-Champaign.

82-84

The Langevin dynamics algorithm, in addition to the force

derived from bonded and non-bonded atomic interactions decribed previously, takes into
account the additive force of random collision and the subtractive force resulting from
friction. 85 The first set of simulations were performed using a canonical ensemle (NVT)
to minimize and equilibrate the solvated protein. (Figure 26) This involved restraining
the protein at fixed atomic coordinates while allowing water molecules to move closer to
the protein. At the same time, a stepwise increase of temperature was performed every

56

Figure 25. Model of periodic unit cell containing the solvated TrmD structure.
Molecular dynamics simulations of SAM-bound and apo-TrmD were performed using cubic
periodic boundary conditions in TIP3P explicit water. The dimensions of the x, y and z unit
cell vectors were determined based on a minimum distance of 15 Å above the largest
Cartesian coordinate of the protein. The protein structure (cyan) is shown in ribbon
representation. The water molecules are represented by red lines and the neutralizing Na+ and
Cl- counterions are shown in yellow and cyan spheres, respectively. The periodic unit cell was
modeled using VMD. 114 (http://www.ks.uiuc.edu/Research/vmd).
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Figure 26. Temperature plot during protein equilibration and minimization in a
canonical ensemble (NVT) simulation. During equilibration, the protein was restraining at
fixed atomic coordinates while allowing water molecules to move closer to the protein. At the
same time, a stepwise increase in temperature was performed every 5,000 timesteps, starting
at 100 K and increasing in increments of 50 K until a final temperature of 300 K was reached.
The restraint on the protein atomic coordinates was then released and an energy minimization
simulation was carried out using the same temperature increments described above. Protein
equilibration and minimization was simulated in a canonical ensemble, (NVT). The program
NAMD 2.7, incorporating CHARMM force field parameters and Langevin dynamics was
used to generate simulation trajectories.
.
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5,000 timesteps starting at 100 K and increasing in increments of 50 K until a final
temperature of 300 K was reached. The restraint on the protein atomic coordinates was
then released and the equilibration steps were repeated. The solvated protein was then
simulated using an isothermal-isobaric ensemble (NPT) at 300 K for a 10 ns production
run. (Figure 27)
The Cα RMSD (root mean square deviation) of individual residues was used to
analyze the trajectories.
Nt
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where Nα is the number of atoms whose positions are being compared, Nt is the number



( )

of time steps over which atomic positions are being compared, rα t j is the position of



atom α at time tj ,and rα



is the average value of the position of atom α to which the

( )

positions rα t j are being compared. Because all amino acids possess a Cα atom as part of
the backbone structure, its position in time can be monitored throughout a trajectory and
fluctuations from its original position is a good indication of residue flexibility.

3.6

Results and discussion

3.6.1 Cα RMSD
Ten nanosecond simulations were generated for both TrmD apoenzyme and
TrmD complexed with SAM using NAMD 2.7. Root mean square deviations per residue
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Figure 27. Temperature plot during an isothermal-isobaric (NPT) production run
simulation. Ten nanosecond production run simulations for SAM-bound and apo-TrmD were
conducted at 300 K using an isothermal-isobaric ensemble, (NPT). The program NAMD 2.7,
incorporating CHARMM force field parameters and Langevin dynamics was used to
generate simulation trajectories
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for C alpha atom fluctuations during the simulation were calculated and plotted in the
graph shown in Figure 28. Two regions enveloping the SAM binding site appear to be
quite mobile, namely a halo loop and a flexible linker strand connecting the C and N
terminus. It is possible that the movement of these regions may serve as a gating function
allowing access to the SAM binding site.
3.6.2 Histidine 162
Also evident on this graph, is the apparent high RMSD value for histidine 162 in
the flexible linker. The protonation state of histidine may vary depending on the local
environment (pka = 6.0). (Figures 29a, 29b and 29c) The default assignment for histidine
protonation in simulations is the HSD state in which the Nδ nitrogen of the histidine
imidazole ring is protonated. This type of histidine residue is usually found in the core of
a protein, away from solvent accessible regions. In the HSP protonation state, both the Nδ
and Nε nitrogens of the histidine imidazole ring are protonated. This type of histidine
residue is predominantly found in solvent accessible regions of the protein. Because the
H162 residue is located on the flexible linker of the E. coli TrmD structure, it is most
likely exposed to solvent. Recall that this region lacked electron density in the X-ray
crystal structure. The simulation was repeated using the doubly protonated histidine state
(HSP) to see if it affects its mobility in the surrounding solvent. A lower RMSD was
observed for this simulation. (Figure 30) To investigate a possible reason for this
decreased flexibilty, the SAM-bound TrmD (HSP) trajectory was analyzed for possible
salt bridge interactions involving residue H162. The Salt Bridge plugin in VMD was used
in this analysis. Two salt bridge interactions involving the doubly protonated H162
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Figure 28. Plot of Cα RMSD during 10 ns simulations of SAM-bound TrmD and apoTrmD. The Cα RMSD measures residue fluctuations during a simulation. The position of the
Cα atom for each residue is monitored throughout the trajectory and a deviation from its
original position is a good indication of its flexibility. The plot above shows two major
regions of the protein with high Cα RMSD values in both the SAM-bound (blue line) and apoTrmD (pink line), namely a linker region and a halo loop. Residues comprising the linker
region which connects the C and N-terminal domains, were missing electron density in the xray crystal structure so it is not surprising that the modeled peptide chain for this region
resulted in higher RMSD values. The halo loop and flexible linker, shown in ribbon
representations above the plot, are located on opposite monomers, constituting an interface
above the active site. Of particular note is a high RMSD value for a histidine residue (H162).
This residue is located on the flexible linker and is modeled in the picture above the plot as a
ball and stick figure. The low RMSD values for residues comprising the SAM binding pocket,
shown on the plot below the chemical structure of SAM, indicate that this region of the
protein is not very flexible. The structures were generated using VMD. 114
(http://www.ks.uiuc.edu/Research/vmd)
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Figure 29. Histidine protonation states. (a) The pka of histidine varies depending on the pH
of the local environment as illustrated above using chemical structures of histidine in different
protonation states. (b) The default assignment for histidine protonation in simulations is the
HSD state in which the Nδ nitrogen of the histidine imidazole ring is protonated. This type of
histidine residue is usually found in the core of a protein, away from solvent accessible
regions. (c) The HSP protonation state is that in which both the Nδ and Nε nitrogens of the
histidine imidazole ring are protonated. This type of histidine residue is predominantly found
in solvent accessible regions of the protein. The structures were generated using VMD. 114
(http://www.ks.uiuc.edu/Research/vmd)
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Figure 30. Plot of Cα RMSD during 10 ns simulations of apo-TrmD, SAM-bound TrmD
and SAM-bound TrmD (HSP). The plot above shows the Cα RMSD (green line) of SAMbound TRMD containing the doubly protonated H162 residue (HSP) as it compares to the Cα
RMSD of the SAM-bound TrmD (blue line) and apo-TrmD (pink line) which contain the
singly protonated H162 residue. A significant decrease in flexibility is observed in the doubly
protonated H162 residue.
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residue were identified. (Figure 31) At different times during the simulation, the H162
residue makes a hydrogen bond between either D169 or E116. The residue D169 is
located on the same flexible linker just above H162 while the E116 residue is located on
the opposite monomer on a loop just below the SAM binding pocket. A salt bridge
analysis of the MD simulation for SAM-bound TrmD (HSD) was also performed but did
not implicate H162 in any salt bridge interactions. The participation of H162 (HSP) in
salt bridge interactions is consistent with the lower Cα RMSD value observed for this
residue compared to H162 (HSD). However, the H162 (HSP) Cα RMSD was still higher
than the surrounding residues. Although H162 is not a conserved residue among TrmD
proteins based on the multiple sequence alignment (Figure 5) presented in Chapter 1, this
finding warranted additional testing. Hence, an H162A mutant was constructed, assayed
and was found to be fully active. (Figure 32) The methodologies and mutagenesis
protocols for H162A are described in chapter 4 along with all other mutational studies.
3.6.3 Cα distance through time between residues H162 and P58
To investigate a possible pattern or coordination of gating movements between
the two sides of the protein, the distance between the flexible linker and halo loop was
measured for the duration of the MD trajectory in both the TrmD SAM and TrmD apoenzyme. The measurements plotted in Figure 33 represent the distance (Å) from the C
alpha atom of residue H162 in the flexible linker to the C alpha atom of residue P58 in
the halo loop. It appears that the movements of the halo and linker regions are somewhat
synchronized between the two sides of the protein in that the binding site on one side is
more accessible while the other side is less accessible and vice versa as illustrated by the
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Figure 31. Salt bridge interactions between H162 and D169 and between H162 and
E116. Analysis of the MD simulation for TrmD (HSP) revealed two salt bridge interactions
involving the doubly protonated H162 residue. At different times during the simulation the
H162 residue makes a hydrogen bond between either D169 or E116. The residue D169 is
located on the same flexible linker just above H162 while the E116 residue is located on the
opposite monomer on a loop just below the SAM binding pocket. A salt bridge analysis of the
MD simulation for TrmD (HSD) did not yield any salt bridges involving the singly protonated
H162 residue. The participation of H162 (HSP) in salt bridge interactions is consistent with
the lower Cα RMSD value observed for this residue compared to H162 (HSD). Residues
H162, D169 and E116 are modeled as licorice figures while the protein is shown in ribbon
representation with the cyan and rose coloration differentiating the two monomers. SAM is
depicted as transparent gray vdW representation in the intact protein figure (top left). Salt
Bridges plugin in VMD was used to analyze the simulation trajectories. The structures were
generated using VMD. 114 (http://www.ks.uiuc.edu/Research/vmd).
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Figure 32. Enzyme activity of E. coli TrmD WT and H162A mutant protein. In vitro
methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-L-methionine was used to
measure TrmD activity of WT protein and protein containing the alanine substituted
mutation, H162A. Activity is reported as percent of WT control. The H162A mutation in
TrmD has no effect on enzyme activity. All experiments were done in duplicate A total
reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM
MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM
(specific activity 10 Ci /mMol), 20 µM tRNALeu and 500 nM E. coli TrmD.
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Figure 33. Plot of Cα distance through time between residues H162 and P58 in SAMbound TrmD and apo-TrmD. The opening to the SAM binding site was measured
throughout a 10 ns simulation as the distance (Å) between the Cα atoms of residues H162 and
P58. These measurements were calculated for both active sites of the protein and are
represented in the graph above as a solid blue line (site 1 of SAM-bound TrmD), solid red
line (site 2 of SAM-bound TrmD), broken blue line (site 1 of apo-TrmD) and broken red line
(site 2 of apo-TrmD). The opening to the SAM binding site for the SAM-bound protein
appears to alternate between a more accessible conformation and a less accessible
conformation (solid lines) and this accessibility is synchronized between the two sides of the
protein such that one side is more accessible while the other side is less accessible (solid blue
and red lines). The opening to the SAM binding site for the apo-protein (broken lines) is not
as synchronized between the two sides. One side appears to be in a more open conformation
than the other side (broken blue and red lines), particularly as the simulation progresses. The
protein is shown in ribbon representation with the cyan and rose coloration differentiating
the two monomers. SAM is depicted as transparent gray vdW representation. The structures
were generated using VMD. 114 (http://www.ks.uiuc.edu/Research/vmd).
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solid lines on the graph. This may suggest a single site mechanism for ligand binding
and or function. It has been previously demonstrated that some proteins having dual
binding sites may utilize only one site.86,87 Analysis of these distances for the apo-enzyme
shown by the dotted lines on the graph, depicts the protein as having equally accessible
openings to the active sites at the beginning of the trajectory. However, during the course
of the trajectory one side becomes more accessible and remains that way for the duration
of the 10 ns simulation. In the absence of ligand, it may be that asymmetry exists, making
one site more attractive for binding. After this binding, the other side may become
accessible to accommodate another SAM substrate. This correlates with ITC data
described in the next chapter which suggest a sequential mode of binding for the cofactor.
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Chapter 4

Half of the Sites Activity in TrmD - Implications for Functional
Interdependence Between Dynamic Structural Elements Across the MonomerMonomer Interface

4.1

Addressing the issue of stoichiometry for TrmD substrates
The binding of SAM and SAH to TrmD was investigated previously in our

laboratory by Dr. Joseph Watts using surface plasmon resonance (SPR) where the protein
was immobilized on a Ni-NTA gold chip. In addition to wild type enzyme, the binding
of several alanine-substituted mutant enzymes were also assessed. Although the
determination of stoichiometry was not extensively pursued since it was not the focus of
that study, it was observed that data was fitted best to the equation for binding when the
ratio of ligand to homodimeric protein was 1:1.

88

This was in contrast to the crystal

structure which showed two ligands bound per dimer.

20

This discrepancy could be

explained by the fact that millimolar concentrations are used for the crystallization
protocol compared to micromolar concentrations for the SPR experiments thus forcing an
unnatural saturation of ligand binding during crystal formation. However, it has also been
noted that SPR-based equilibrium constants do not necessarily match those obtained from
solution-based methods. For example, the retention of a protein on a gold chip surface
could restrict its rotational freedom and diffusional properties, which could substantially
70

alter the thermodynamics of the reaction and binding kinetics.

89

A recent paper by

Christian et al. suggested a stoichiometry of 1:2 for SAM:TrmD and 1:1 for tRNA:TrmD
using fluorometric methodologies based on intrinsic fluoresence.90 However, previous
unpublished data from our laboratory suggests that intrinsic fluorescence is unaffected by
the binding of either substrate. For this reason, along with implications of dynamic
structural asymmetry surrounding the active sites as suggested by the molecular
dynamics simulations, we sought to determine stoichiometry of binding for SAM, SAH
and tRNA using ITC, a solution-based methodology.
4.2

Theory of isothermal titration calorimetry
Isothermal titration calorimetry is an important tool in biophysical chemistry due

to its ability to characterize thermodynamics of a binding event in a single experiment. It
allows the simultaneous determination of the binding affinity (Ka), enthalpy (ΔH) and
stoichiometry (n) and subsequent calculation of Gibbs free energy (ΔG) and entropy (ΔS)
of a reaction.

In addition, the technique offers rapid thermodynamic analysis of a

biomolecular system without the need to chemically modify or immobilize the
perspective macromolecule. ITC directly measures the heat released or absorbed by the
stepwise titration (injection) of one reactant into a sample cell containing the other. This
is done by comparing the temperature of the sample cell after injection of ligand to a
reference cell which usually contains only buffer and determining the amount of heat
needed to add or remove to the sample cell in order to maintain the same temperature as
the reference cell. (Figure 34) The amount of heat released or absorbed by a chemical
reaction created by each injection is proportional to the amount of ligand that binds to the
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Figure 34. Schematic diagram of an isothermal titration calorimeter. As ligand in the
syringe is titrated into the sample cell which usually contains the macromolecule or
protein, heat is either absorbed (endothermic reaction) or released (exothermic reaction)
proportional to the amount of binding. This causes a change in the temperature of the
sample cell compared to the reference cell containing only buffer (∆T1), which is relayed
back to a power supply. In return, a feed back mechanism either decreases or increases
power to the sample cell in order to maintain the same temperature as the reference cell.
The reference cell is maintained at a constant temperature by the power supply which is
monitored as ∆T2. The raw data obtained is the power (µJ/s) required to maintain the
sample cell at the same temperature as the reference cell versus the time for each
injection. Integration of the power versus time data results in the heat released or absorbed
during each injection.
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protein for that particular injection and the binding enthalpy for the reaction. Over the
course of the experiment, the system becomes saturated with ligand leading to relatively
small, uniform heats. These small uniform peaks correspond to the heats of dilution upon
injection of the ligand which are subtracted from the experimental heats of each injection
prior to data analysis. The heat changes are then normalized with respect to the moles of
ligand injected and plotted against injection number or molar ratio of components. Since
all equilibrium constants vary with temperature, according to Van’t Hoff equation, we
can calculate the affinity constant:

d ln K ΔH
=
dT
RT 2
where K is the equilibrium constant, T is the absolute temperature, H is enthalpy and R is
the gas constant. The equilibrium constant is also related to the Gibbs free energy (ΔG) of
binding by the reaction:
ΔG = −nRT ln K

where n is the number of binding sites, R is the gas constant K is the equilibrium
constant. Since the ΔHobs is measured directly from the ITC experiment, we can also
calculate the reaction entropies (ΔS) from the reaction:
ΔG = ΔH − T ΔS

Determination of ΔH, K, and n are made by fitting the heat released or absorbed to
changes in the total concentration of ligand. Using nonlinear least-squares analysis, the
data can then be fitted to different binding models.
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4.3

Allosteric inhibition in homodimeric proteins
Current therapeutic approaches exploit features of dimeric proteins for the

development of allosteric inhibitors. It has been proposed that the monomer-monomer
interface is a particularly attractive target for selective drug design because the amino
acid conservation is usually lower in this region compared to conservation of residues
comprising the active site (s). 91
4.3.1 Therapeutic implications of allosteric inhibition
There are a number of ongoing research efforts currently focusing on allosteric
inhibition of clinically significant dimeric proteins by targeting monomer interface
interactions.91 Recently, promising research has been reported for the allosteric inhibition
of human thymidylate synthase (hTS), a clinically important anti-cancer drug target.92
This enzyme is involved in the folate pathway and catalyses the reductive methylation of
2’-deoxyuridine-5’monophosphate

(dUMP)

to

form

2’deoxythymidine-5’-

monophosphate (dTMP) using the cofactor N5, N10 methylenetetrahydrofolate (mTHF).
Thymidylate synthase, like TrmD, is a homodimeric protein with dual active sites, each
one formed by residues from both monomers. It has been reported to have half-site
activity. A sixteen residue loop above each active site contains a catalytic cysteine
responsible for the deprotonation of dUMP. This loop takes on a different conformation
in the ligand-bound enzyme, rotating 180° from its unliganded state to bring the cysteine
into the active site. When the cysteine is pointing into the active site, the enzyme is said
to be in the active form and conversely, when the cysteine is pointing away, the enzyme
is said to be in the inactive form. When the enzyme is in the inactive conformation it can
bind to its own mRNA to inhibit protein synthesis. In addition, the inactive conformation
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is subject to degradation. When the enzyme is in the active conformation, for example
when the active site is occupied by either endogenous substrates or exogenous drug
inhibitors it is not able to bind mRNA or be degraded which leads to increased
intracellular levels of TS. This induction of TS in cancer cells treated with active site
inhibitors such as pemetrexed, FUra or FDUrd is thought to play a role in drug resistance.
Recently, efforts to identify peptide inhibitors that destabilize enzyme dimerization led to
the discovery of a peptide sequence that inhibits enzyme activity by binding to a region
on the dimer interface which actually stabilizes the inactive form. This allosteric
inhibition has the advantage of inhibiting intracellular TS without the induction of its
overexpression. Ovarian cancer cell lines transfected with micromolar concentrations of
this peptide showed promising results. 92
Another important dimeric protein target is the HIV-1 protease (PR) which is
responsible for the hydrolysis of gag and gag-pol polyproteins.

93

This cleavage releases

individual proteins and enzymes required for biological activity of the virus. Recently,
novel computational approaches have been used to identify “hot spots” between the PR
monomer interface that could potentially focus the development of new drugs aimed at
disrupting dimerization. Alanine scanning mutagenesis (ASM) and molecular dynamics
simulations were used to identify structural and energetic determinants for dimer
formation. ASM was used to determine differences of binding free energy (ΔΔGbinding) for
interface residues that had been mutated in silico to alanine. This allows the identification
of amino acid residues that contribute the most to binding of the two monomers. The
molecular dynamics simulations were used to monitor hydrogen bonding between
residues throughout a 10 ns trajectory. Some of the residues that maintained hydrogen
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bonding for the longest interval of time during the trajectory were also implicated by the
ASM ΔΔGbinding analysis. Other dimeric proteins currently being targeted for monomer
interface analysis, include HSV protease, human glutathione reductase, inducible nitric
oxide synthase, HIV integrase, Lactobacillus casei thymidylate synthase, IgG1
Streptococcal protein G, as well as many others. 91
4.3.2 Relevance of allosteric inhibition in TrmD
The concept of allosteric inhibition is particularly relevant for an enzyme like
TrmD which uses the ubiquitous methyl donor SAM, a substrate in many
methyltransferases.94 SAM is the second most commonly used substrate in nature, second
only to ATP.95 Substrates of SAM dependent methyltransferases include DNA, RNA,
polysaccharides and lipids.

96,97

SAM dependent methyl transfer has been implicated in

protein tertiary structure, intracellular signaling, and histone packing.

98-100

Analogs of

SAM have been recently shown to inhibit both the bacterial TrmD as well as the Archeal
Trm5, a protein assumed to be nearly identical to the human Trm5 enzyme.101 This
underscores the importance of pursuing allosteric modes of inhibition for TrmD.
Understanding the structural basis for the dynamic interactions between the two catalytic
centers of this homodimeric protein can be very useful for the development of
therapeutics to target protein function. To this end, mutational studies have been designed
involving residues across the monomer-monomer interface to elucidate a possible
interdependence mechanism between the dual catalytic centers.
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4.4

Design rationale for mutational studies
To address the question of functional interdependence between the two catalytic

centers of TrmD, several mutatational studies were designed. One of the issues we
wanted to address was whether or not impeding the mobility of one side of the molecule
by an engineered disulfide bond would have an effect on the other side. Given that the
catalytic centers are at the interface of the two monomers, it is reasonable to expect that
this type of interdependence may exist. We also wanted to compare activity to another
type of mutant protein possessing a mutation on one side which would render that side
inactive but would presumably not impede on its structural mobility. The mutation
D169A is an ideal candidate since this residue is assumed to play a role in catalysis by
deprotonating the N1G37 of tRNA. This residue was therefore used as a control. In order
to identify candidate residues for cysteine substituted mutagenesis, the structure was
analyzed by a genetic algorithm used by the software Disulfide by Design.™
4.5

Materials and Methods

4.5.1 Isothermal titration calorimetry
Sample preparation
ITC measurements were obtained using the MicroCal iTC200 (GE Healthcare)
calorimeter. Purified E. coli TrmD was dialyzed overnight in 4 Liters of assay buffer (100
mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM MgCl2, 0.1mM EDTA) at 4 °C.
Approximately 500 mL of the dialysis buffer was retained and filtered using Nalgene
Fast-Flow (Thermo Scientific®) membrane containing a pore size of 0.2 micron. Stock
solutions of protein, SAM, SAH and tRNA were made using the filtered buffer. The
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concentration for TrmD was determined using UV (OD280) absorbance measurements and
the extinction coefficient of 72620 cm-1 M-1.102 The concentrations for SAM and SAH
were determined using UV (OD260) absorbance measurements and the extinction
coefficient of 15400 cm-1 M.-1

103 104

The tRNA concentration was determined using UV

(OD260) absorbance measurements and the extinction coefficient of 28029 cm-1 M-1. All
solutions were degassed in vacuum for 30 minutes immediately prior to loading on the
calorimeter.
Calorimeter setup and experimentation
For the TrmD-SAM binding isotherm measurements, 200 µL of TrmD (90 µM)
were placed in the sample cell and 40 µL of SAM (1.6 mM) were placed in the
microsyringe. The reference cell was filled with the degassed dialysis buffer described
previously. Thirty injections of SAM (1.3 µL each) were titrated into the sample cell
containing TrmD while the solutions were continuously mixed by a rotor set at 1000 rpm.
The titrations were spaced 120 seconds apart. The setup was similar for the TrmD-SAH
binding isotherm measurements with the exception of the concentration of TrmD in the
sample cell which was 72 µM. For the TrmD-tRNA isotherm measurements, the
concentration of tRNA in the microsyringe was 150 µM while the enzyme concentration
in the samples cell was 10.8 µM. Sixteen injections of tRNA (2.5 µL each) were titrated
into the sample cell at intervals spaced 4 minutes apart. The internal mixing rotor was set
to 300 rpm in accordance with previously published ITC settings for RNA binding.

105

The calorimeter was set to 25 °C for all three substrate binding experiments. Control
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titrations were also performed and included those in which substrate was titrated into
buffer and buffer titrated into protein sample.
Fitting data to different binding models
Data collected from ITC experiments were fitted to different binding models
using Origin 7.0 software (OriginLab® corp.). Three types of models were evaluated and
included the ‘Single Set of Identical Sites’ model, the ‘Two Sets of Independent Sites’
model and the ‘Sequential Binding Sites’ model. The equations for fitting the integrated
heats released or absorbed during a binding reaction are dependent on the specific
binding model used.
‘Single Set of Identical Sites’ model
The ‘Single Set of Identical Sites’ model implies that the macromolecule has one
or more substrate binding sites with identical affinity and thermodynamic attributes. In
the case of TrmD, a homodimeric protein possessing two potential substrate binding sites,
this model could be used to identify either a single site binding event or a dual site
binding event, each site possessing identical binding affinities and thermodynamic
attributes. Using this model, the equation for fitting the heat (Q) obtained from each
titration peak is as follows:

Q = nΘM t ΔHV0

where Q is the total heat content of the solution contained in the sample cell, n is the
number of binding sites, Θ is the fraction of sites occupied by substrate, Mt is the molar
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concentration of the macromolecule in the sample cell, H is the molar heat of substrate
binding and V0 is the working volume in the sample cell.

‘Two Sets of Independent Sites’ model
The ‘Two Sets of Independent Sites’ model implies that the macromolecule
possesses two sets of independent binding sites, each set with a distinct affinity and
thermodynamic attributes for substrate binding. In other words, the affinity of substrate at
one set of sites, is unaffected by the presence of substrate at the other set of sites. This
model also allows for numerous binding sites (n), each site within the set possessing
identical binding affinities. Using the ‘Two Sets of Independent Sites’ model, the
equation for fitting the heat (Q) obtained from each titration peak is as follows:

Where Q is the total heat content of the solution contained in the sample cell, Mt is the
molar concentration of the macromolecule in the sample cell, V0 is the working volume
in the sample cell, n1 and n2 are the number of binding sites for each set of sites, Θ 1 and

Θ 2 are the fraction of sites occupied by substrate for each set of sites, and H1 and H2 are
the molar heats of substrate binding for each set of sites.
‘Sequential Binding Sites’ model
The ‘Sequential Binding Sites’ model characterizes the binding mechanism for a
macromolecule possessing multiple binding sites in which the binding of substrate at one
site is influence by the presence of bound substrate at any of the other binding sites. This
model can be used to elucidate interacting sites. The terminology used to describe this
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binding mechanism is written in terms of the order of substrate binding, i.e., “first”
substrate binding, “second” substrate binding, etc. This is in contrast to the other two
models discussed previously, which characterize the binding event in terms of binding
sites. Using the ‘Sequential Binding Sites’ model, the equation for fitting the heat (Q)
obtained from each titration peak is as follows:

Where Q is the total heat content of the solution contained in the sample cell, Mt is the
molar concentration of the macromolecule in the sample cell, V0 is the working volume
in the sample cell, F1, F2, … Fn correspond to the fraction of macromolecule bound to
substrate after the “first”, “second”, and nth substrate molecules are bound, and H1,
H2,…Hn correspond to the molar heat of binding for the “first”, “second”, and nth bound
substrate molecule.
Determination of ΔQ(i) following each titration
For all three models, the change in heat after each injection can be calculated
using the following equation:

Where Δ Q(i) is the difference in heat released or absorbed between ith injection heat ( Q(i)
) and the ith-1 injection heat (Q(i-1) ), dV(i) is the displaced volume (injection volume for
the ith injection), and V0 is the working volume in the sample cell. The Origin 7.0
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software then utilizes the Marquardt minimization algorithm to fit the calculated heats
along with the other parameters to a specific binding model. 106

Chi square (χ 2) analysis
The chi square (χ 2) minimization equation was used to assess the “goodness of
fit” of the ITC experimental data to each of the binding models. This equation states that
the chi squared value of the fit is equal to the sum of the squares of the deviations of the
theoretical curve(s) from the experimental points divided by the number of degrees of
freedom. The following equation describes the chi square analysis as it pertains to ITC
data:

!2 =

2
1
#$ yi " f ( xi ; P1, P2 ,...) %&
'
n "P
eff

where neff is the total number of experimental points used (i.e., number of injections), P is
the total number of adjustable parameters defined by the specific binding model, yi is an
individual experimental data point, and f [(xi ; P1 P2 …)] is defined as the fitting function
pertaining to a specific binding model with Pi parameters.
4.5.2 In silico evaluation of cysteine residues for mutagenesis
Engineered disulfide bonds are often used to increase protein stability and to
assist in the study of protein dynamics and function.

107 108 109

To gain a better

understanding of the dynamic contributions of the linker and halo regions of the protein
which are located at the monomer-monomer interface above the active site, we wanted to
identify cysteine substituted residues that could potentially form a disulfide bond across
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this interface. A program has been developed by Dombkowski et al., Disulfide by
Design™, which uses a genetic algorithm to analyze optimal geometry for disulfide bond
formation in a protein and predict ideal residue candidates for cysteine mutations. 110 This
program uses a fixed Cβ-Cβ distance based on atomic Cartesian coordinates of the
protein (in the case of glycine residues, Cβ coordinates are guessed) and assesses
different orientations of Sγ atoms that will give the lowest energy based on χ1 and χ3
torsion angles and the two Cα-Cβ-Sγ angles. The energy calculation predicts a minima at
χ3 angle torsion equal to -80° or +100° with a tolerance of up to 30° deviation. This
range of acceptable torsion angles is based on a study performed by Petersen et. al. in
which Cartesian coordinates from over 300 crystallized protein structures were assessed
for disulfide χ3 geometry.111 For this study, five different conformations of TrmD
obtained from the simulation trajectories were analyzed using the program Disulfide by
Design.™.
4.5.3 Mutation and cloning protocols
Homodimeric single residue mutagenesis: H162A, A164C, P58C, D169A
The pET28b plasmid containing the WT E. coli trmD gene was purified from 5
mL overnight grown cultures using QIAprep Spin Miniprep Kit (QIAGEN) in
accordance with manufacturer’s recommendations. The sequence of a pET28b plasmid
containing the D169A mutated trmD gene, previously mutated by Joe Watts in our
laboratory, was confirmed by VCU DNA core facilities using T7P primers. A standard
protocol was followed for mutagenesis using the QuickChange II Site-Directed
mutagenesis kit from Agilent-Stratagene. The forward and reverse primers for the
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H162A, A164C, and P58C mutations were 5' CCG GGA GTA CTG GGA GCT GAA
GCC TCG GCA AC 3', 5' GT TGC CGA GGC TTC AGC TCC CAG TAC TCC CGG
3', 5' G GGA GTA CTG GGA CAT GAA TGC TCG GCA ACG GAA GAT TCC 3', 5'
GGA ATC TTC CGT TGC CGA GCA TTC ATG TCC CAG TAC TCC C 3' and 5' CGT
CCT TAC GGC GGC GGA TGT GGG ATG TTA ATG ATG GTG 3', 5' CAC CAT
CAT TAA CAT CCC ACA TCC GCC GCC GTA AGG ACG 3', respectively. Changed
nucleotides are indicated in bold type. Each 50 µL reaction mixture contained 1.5 µL of
forward primer (100 ng/µL), 1.5 µL of reverse primer (100 ng/µL), 2.0 µL of plasmid
DNA (25 ng/µL) 1.0 µL of PFuUltraTM High-Fidelity DNA polymerase (2.5 U/µL), 5.0
µL of 10× reaction buffer, 1.0 µL of dNTP mix, and 38.0 µL of nuclease free ddH2O
(Quality Biological Inc.). The following PCR cycling parameters were used: initial
denaturation step (95 °C for 3 minutes), twenty-five cycles of amplification steps
(denaturation at 95 °C for 50 seconds, annealing at 55 °C for 60 seconds, extension at 68
°C for 8 minutes) and a final extension step (68 °C for 10 minutes). Each PCR sample
was then treated with 1.0 µL of the enzyme Dpn I (10 U/µL) followed by a one hour
incubation period at 37 °C in order to digest the methylated parental DNA template and
to select the newly synthesized non-methylated template containing the mutation.
Following Dpn I digestion, 5.0 µL of each reaction sample was added to 50 µL of prechilled XL1-Blue supercompetent cells (Agilent-Stratagene) for transformation. A
standard heat shock protocol was used in which the samples were incubated on ice for 30
minutes followed by a 45 second incubation at 42 °C and subsequent 2 minute incubation
on ice. 500 µL of LB broth was then added to each sample and the mixtures were
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incubated for one hour at 37 °C on a rotary shaker set to 225 rpm. Following incubation,
the cells were plated on agar plates containing kanamycin and were incubated at 37 °C
for at least 24 hours. Successful transformants were used to inoculate 5.0 mL of LB broth
culture tubes containing kanamycin and were grown overnight. Plasmids were extracted
using the QIAprep Spin Miniprep Kit (Qiagen) in accordance with manufacturer’s
recommendations and sequenced by VCU DNA core facilities using T7P primers.
Plasmids containing single residue mutations for H162A, A164C, P58C, or D169A were
transformed into Rosetta2 (DE3) competent cells using the standard heat shock
protocol described previously. Cells were plated and grown in media containing both
kanamycin and chloramphenicol. Expression and purification protocols for mutant and
WT proteins were similar to those described previously with one exception: DTT was
excluded from the dialysis buffer. A 10% SDS-PAGE gel (Bio-Rad) was used to
visualize the recombinant mutant proteins. Structural representations of these mutations
are shown in Figures 35a, 35b and 35c.

Homodimeric double residue mutagenesis: P58C-A164C
The P58C-A164C double mutant TrmD was constructed using the P58C plasmid
as template DNA and the forward and reverse primers for A164C. A standard protocol
was followed for mutagenesis as described previously using the QuickChange II SiteDirected mutagenesis kit from Agilent-Stratagene. Expression and purification protocols
were the same as those of the single residue recombinant mutant proteins. A structural
representation of these mutations is shown in Figure 36.
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Homodimeric triple residue mutagenesis: P58C-A164C-C112A and P58C-A164C-C178A
The P58C-A164C-C112A triple mutant TrmD was constructed using the P58CA164C plasmid as template DNA and the C112A forward and reverse primers, 5' CAA
AAA TTG ATT CTG GTG GCC GGT CGC TAC GAA GGT ATA G 3' and 5' C TAT
ACC TTC GTA GCG ACC GGC CAC CAG AAT CAA TTT TTG 3', respectively. The
P58C-A164C-C178A triple mutant TrmD was constructed using the P58C-A164C
plasmid as template DNA and the C178A forward and reverse primers, 5' CT GAA GGA
TTG CTG GAT GCC CCG CAC TAT ACG CGG 3' and 5' CCG CGT ATA GTG CGG
GGC ATC CAG CAA TCC TTC AG 3', respectively. Changed nucleotides are shown in
bold type. A standard protocol was followed for mutagenesis as described previously
using the QuickChange II Site-Directed mutagenesis kit from Agilent-Stratagene.
Expression and purification protocols were the same as those of the single and double
residue recombinant mutant proteins. Structural representations of these mutations are
shown in Figure 37a and 37b
Cloning of heterodimeric and homodimeric mutant and wild type proteins: WT/WT,
WT/P58C, WT/D169A, and 00/WT
The pCDFDuet-1 plasmid was used in the construction of heterodimeric TrmD protein.
This plasmid contains two multiple cloning sites (MCS) each of which is preceded by a
T7 promoter. (Figure 38) The MCS-1 region contains an N terminal (His)6 tag which
allows for protein immobilization using a Ni-NTA affinity chromatography. The MCS-2
region, contains a C-terminal S-tag (15 amino acid sequence) which allows recombinant
protein to be immobilized on S protein resin. The S protein, originally derived from
ribonuclease A, has a very strong affinity for the S-tag peptide, also a component of
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Figure 35. Structural representations of the homodimeric single residue mutations in E.
coli TrmD: A164C, P58C, D169A. Single residue mutations in E. coli TrmD were made
using the QuickChange II Site-Directed mutagenesis kit from Agilent-Stratagene. The
protein is shown in ribbon representation with the gray and olive coloration differentiating the
two monomers. SAM is depicted as licorice figure. (a) The A164C mutated residue is located
on the flexible linker of each monomer and is modeled in red vdW representation. (b) The
P58C mutated residue is located on the halo loop of each monomer and is modeled in blue
vdW representation. (c) The D169A mutated residue is located in the flexible linker of each
monomer and is modeled in green vdW representation. The structures were generated using
VMD.114 (http://www.ks.uiuc.edu/Research/vmd)
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Figure 36. Structural representation of the homodimeric double residue mutant, P58CA164C, in E. coli TrmD. The double residue mutations in E. coli TrmD were made using the
template cDNA of the P58C mutant and the QuickChange II Site-Directed mutagenesis kit
from Agilent-Stratagene. The protein is shown in ribbon representation with the gray and
olive coloration differentiating the two monomers. SAM is depicted as a licorice figure. The
P58C mutated residue is located on the halo loop of each monomer and is modeled in blue
vdW representation. The A164C mutated residue is located on the flexible linker of each
monomer and is modeled in red vdW representation. The structures were generated using
VMD. 114 (http://www.ks.uiuc.edu/Research/vmd)
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Figure 37. Structural representations of the homodimeric triple residue mutations in
E. coli TrmD: P58C-A164C-C112A and P58C-A164C-C178A. The triple residue
mutations in E. coli TrmD were made using the template cDNA of the double residue mutant,
P58C-A164A and the QuickChange II Site-Directed mutagenesis kit from AgilentStratagene. The protein is shown in ribbon representation with the gray and olive coloration
differentiating the two monomers. Both of the triple residue mutants contain the A164C
mutated residue located on the flexible linker of each monomer (modeled in red vdW
representation) and the P58C mutated residue located on the halo loop of each monomer
(modeled in blue vdW representation). In addition, the P58C-A164C-C112A triple residue
mutant (a) contains the C112A mutated residue located on a loop under the SAM binding site
(modeled in orange vdW representation) and the P58C-A164C-C178A triple residue mutant
(b) contains the C178A mutated residue located on a small segment just past the flexible
linker on the carboxy terminus (modeled in magenta vdW representation). The structures were
generated using VMD. 114 (http://www.ks.uiuc.edu/Research/vmd)
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Figure 38. MAP of the pCDFDuet-1 dual promoter cloning region. The pCDFDuet-1
plasmid was used to make the hybrid mutant proteins by taking advantage of the dual
promoter cloning regions, each of which contains a sequence for a different affinity tag. The
dual T7 promoter regions are highlighted in green. The multicloning sites (MCS-1, MCS-2)
are highlighted in yellow; the His-Tag region, preceding MCS-1, is highlighted in blue. The
S-tag region, following MCS-2, is highlighted in red. The restriction endonucleases used to
clone the trmD cDNA into the multicloning sites are outlined in dashed boxes. The
PCDFDuet-1 map was modified from the Novagen® handbook.
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ribonuclease A. 112 The basic scheme involved in the construction of heterodimeric TrmD
protein was: (a) the co-expression of differentially tagged mutant and WT TrmD
monomers cloned into pCDFDuet-1 (Novagen) plasmid and (b) purification of
differentially tagged dimeric protein using dual affinity chromatography. (Figures 39a
and 39b)
Primers were designed to clone the trmD cDNA template from pET28 plasmid
incorporating the BamH I and Sal I restriction sites for insertion into pCDFDuet MCS-1
region and Nde I and Hho I restriction sites for insertion into the pCDFDuet MCS-2
region. The MCS-1 trmD insert was amplified from pET28 TrmD plasmid using the
upstream primer (with BamH I restriction site sequence shown in bold) 5' G CGG GCG
GAT CCG ATG TGG ATT GGC ATA ATT AGC CTG 3' and the downstream primer
(with Sac I restriction site shown in bold) 5' GCG GGC GAG CTC TTA CGC CAT
CCC ATC ATG TTT ATG 3'. The MCS-2 trmD insert was amplified using the upstream
primer (with Nde I restriction site shown in bold) 5' GC GAA GGC CAT ATG TGG
ATT GGC ATA ATT AGC CTG TTT C 3' and the downstream primer (with Hho I
restriction site shown in bold and thrombin cleavage site underlined) 5' GCG GGC CTC
GAG GCT GCC GCG CGG CAC CAG CGC CAT CCC ATC ATG TTT ATG 3'. It
should be noted that the ‘stop’ codon was removed from the gene sequence using the
MCS-2 downstream primer to allow incorporation of the C-terminus S-tag during protein
translation. The pCDFDuet plasmid contains a single T7 terminator sequence following
the MCS-2 region. The Phusion® High fidelity PCR master mix (Thermo Scientific) was
used to amplify the TrmD insert. Each 50 µL PCR samples contained 25 µL of 2×
Phusion® Master Mix (400 µM of each dNTP, 0.04 U/µL Phusion® DNA Polymerase,
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Figure 39. A schematic diagram highlighting the cloning and purification protocols used
in the production of differentially tagged heterodimeric WT and mutant TrmD proteins
(a) Primers were designed containing the BamH I and Sac I restriction endonuclease sites to
clone the trmD cDNA template into the MCS-1 of pCDFDuet-1 plasmid. Primers for the
MCS-2 cDNA insertion were designed with the Nde I and Hho I restriction endonuclease sites
including a thrombin cleavage site noted as TC on the diagram above. (b) Successful clones
were transformed into Rosetta2 (DE3) Competent Cells for protein expression. Protein
purification involved a sequence of two affinity chromatography processes in which the
protein was first immobilized on a Ni-NTA resin followed by a second immobilization using
an S-Protein resin to produce a differentially tagged heterodimeric protein.

92

2× Phusion® HF Buffer, 1.5 mM MgCl2), 1.5 µL DMSO (100%), 2.0 µL of upstream
primer (100 ng/µL), 2.0 µL of downstream primer (100 ng/µL), 2.0 µL of plasmid DNA
(25 ng/µL) of P58C, D169A, or WT TrmD, and 17.7 µL of nuclease-free ddH2O (Quality
Biological Inc.). The following PCR cycling parameters were used: initial denaturation
step (98 °C for 45 seconds), thirty cycles of amplification steps (denaturation at 98 °C for
8 seconds, annealing at 69°C for 25 seconds, extension at 72 °C for 30 seconds) and a
final extension step (72 °C for 8 minutes). An initial annealing temperature gradient was
performed ranging from 65 °C to 72 °C. All annealing temperatures within this range
yielded the same quantity of amplified insert as noted on 1.5% agarose gel stained with
ethidium bromide, shown in Figure 40a for WT MCS-1 trmD template. The DNA bands
corresponding to trmD insert (~ 800 bp) were excised from the gels and were purified
using the isolate PCR and Gel kit from Bioline. The PCR steps were repeated using the
gel-extracted DNA templates in order to amplify each sample. (Figure 40b) The
amplified templates were gel-extracted as described previously. The MCS-1 and MCS-2
trmD cDNA templates for P58C, D169A, and WT were then sequenced by VCU DNA
core facilities using the previously described primers. To rule out potential discrepancies
in enzyme activity resulting from the location of the affinity tag with respect to the
monomer containing the mutant residue, we initially sought to clone the mutant trmD
templates in both MCS-1 and MCS-2 regions of the plasmid in order to create the
following protein dimers: WT/D169A, D169A/WT, WT/P58C and P58C/WT. However,
not all cloning attempts were successful and subsequently, only the WT/P58C,
WT/D169A and the control 00/WT, WT/WT clones were attained. Standard cloning
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Figure 40. Agarose gel electrophoresis showing PCR product from an annealing
temperature gradient and template amplification. (a) An annealing temperature
gradient, ranging from 65 °C to 72 °C, was assessed for the PCR reaction. All annealing
temperatures yielded adequate PCR product as shown above ~800 bp range on 1.5%
agarose gel stained with ethidium bromide. (b) The ~800 bp fragment was gel-extracted
and amplified by a second PCR reaction shown above in the first four electrophoresed
lanes of the gel. The last lane on the right shows the PCR product from intact plasmid. An
aberrant amplification is also noted on the gel as a thin band above the 800 bp trmD
template. Both gels above show PCR product from WT MCS-1 trmD amplification. Half
of each PCR product (25 µL) was loaded on the gel which was then electrophoresed in 0.5
× TBE buffer for 30 minutes at 90 V.

94

protocols were followed. Both the MCS-1 inserts (from P58C, D169A, and WT) and
pCDFDuet plasmid were digested with BamH I and Sac I (New England BioLAb®) in
accordance with manufacturer’s recommendations to create sticky ends. The digests were
purified using the isolate PCR and Gel kit (Bioline) and a ligation reaction was set up
using T4 DNA ligase from New England BioLAb®. Transformation into XL1-Blue
supercompetent cells was attempted for all three ligated plasmids using the protocol
described previously with the exception that cells were plated on streptomycin containing
culture plates. However, only the plate containing WT transformed cells resulted in
colony formation. Four colonies were picked and grown overnight in 5 mL LB broth.
Plasmids were extracted using the QIAprep Spin Miniprep Kit (Qiagen) and sequenced
by VCU DNA core facilities using the downstream primer (VCU DNA core facilities) 5'
GGA TCT CGA CGC TCT CCC T 3'. Two of the four clones resulted in successful
insertion of WT trmD gene in the MCS-1 region of pCDFDuet plasmid. This plasmid
was then used as a template for the insertion of P58C, D169A, and WT MCS-2 trmD
inserts. The WT trmD insert was also cloned into the MCS-2 region of the original
pCDFDuet plasmid resulting in the 00/WT clone. The cloning of MCS-2 inserts was
achieved using the restriction enzymes Nde I and Xho I (New England BioLAb®) in
accordance with manufacturer’s recommendations, followed by the same ligation and
transformation protocols described previously. It took numerous cloning attempts before
all desired clones were achieved. Successful clones which included WT/WT, WT/P58C,
WT/D169A and 00/WT plasmids were transformed into Rosetta2 (DE3) competent
cells and grown in streptomycin and chloramphenicol containing media. Structural and
schematic representations of these mutations are shown in Figures 41a, 41b, 41c and 41d.
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Figure 41. A structural and schematic representation of the WT/P58C, WT/D169A,
WT/WT and 00/WT proteins. The protein structure is shown in ribbon representation with
the gray and olive coloration differentiating the two monomers. The P58C and D169A
mutated residues are modeled in blue and green vdW representations, respectively, and SAM
is modeled as a licorice figure. A schematic diagram to the right of each protein structure
highlights the affinity tag associated with each monomer. The proteins were constructed using
the dual promoter pCDFDuet-1 plasmid and are described as follows: (a) WT/WT (WT
monomer with N-terminus his-tag bound to WT monomer with C-terminus S-tag, (b)
WT/P58C (WT monomer with N-terminus his-tag bound to P58C monomer with C-terminus
S tag), (c) WT/D169A (WT monomer with N-terminus his-tag bound to D169A monomer
with C-terminus S-tag) and (d) 00/WT (both monomers of this WT dimer contain C-terminus
S-tag). The structures were generated using VMD.114 (http://www.ks.uiuc.edu/Research/vmd)
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Expression and purification of WT/WT, WT/P58C, WT/D169A, and 00/WT proteins
One liter cultures of all four proteins were grown and cell pellets were obtained as
described previously. The pellets of WT/WT, WT/P58C, and WT/D169A were processed
and purified using the Ni-NTA method described previously since recombinant proteins
from these cultures contained the N terminal (His)6 tag. The eluates from the nickel
column were dialyzed in bind/wash buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl,
0.1% Triton X) to exchange buffer to that suitable for S-agarose chromatography as well
as to remove imidazole. The pellet from the 00/WT culture was treated directly with 25
mL of bind/wash buffer, lysed using the French press and centrifuged as described
previously. The supernatant of 00/WT and the dialyzed protein mixtures from WT/WT,
WT/P58C, and WT/D169A were each added to 2 mL of S-protein resin (Novagen). The
mixtures were then incubated at room temperature on an orbital shaker for 30 minutes.
After incubation, the samples were centrifuged at 500 × g for 10 minutes decanting the
supernatant. Five mL of bind/wash buffer was added to each sample, mixed gently and
centrifuged again as described above. The buffer addition and centrifugation steps were
repeated two more times. Elution of S-tagged protein was achieved using 3 M MgCl2.
After the third centrifugation step, 4 mL of 3 M MgCl2 was added to each sample and
followed by a ten minute room temperature incubation. The samples were once again
centrifuged at 500 × g for 10 minutes and the supernatant containing the S-tagged protein
was carefully removed from the resin. It was noted that significant precipitation was
occurring in all four protein samples after addition of MgCl2 which persisted even after
an overnight dialysis in sodium phosphate buffer pH 7.5 (50 mM sodium phosphate pH
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7.5, 50 mM NaCl, 10% glycerol). In an effort to bypass the MgCl2 elution step, new
cultures of WT/WT, WT/P58C, WT/D169A and 00/WT were grown and processed as
described above except that thrombin was used to cleave the protein from the S-protein
resin. The thrombin was then removed using a benzamidine agarose column. However,
after multiple dialysis steps due to the numerous buffer exchange requirements for this
protocol, the protein yield was low and of poor quality. Another option would have been
to use biotinylated thrombin followed by thrombin removal with streptavidin agarose
which is the recommended method by Novagen and is sold in kits along with the Sprotein resin. This protocol requires less processing of the protein since it utilizes
compatible buffers which minimize the need for buffer exchange dialysis. However, this
was a more costly option and it was decided to use the MgCl2 eluted protein for the
enzyme assays since precipitation in these samples had ceased after several days of
storage in -20°C.

4.6

Results and discussion

4.6.1 Isothermal titration calorimetry experiments
ITC data measuring the energetics of SAM, SAH and tRNA binding to E. coli
TrmD were obtained using the MicroCal iTC200 (GE Healthcare) calorimeter at the
University of Richmond with permission and guidance from Dr. Dianne Kellogg,
Director of Instrument Facilities, Gottwald Center for the Sciences. The data was fitted
using Origin 7.0 software (OriginLab® corp.)
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The raw data thermogram obtained from SAM-TrmD ITC experiments was
characterized by exothermic heats of binding which decreased in magnitude with each
successive injection of SAM until TrmD saturation was achieved. (Figure 42, top panel)
Integrated heat pulse intensities were evaluated using three different binding models:
‘single set of identical sites’, ‘two sets of independent sites’ and ‘sequential binding’. The
‘single set of identical sites’ model resulted in a non-integer stoichiometry of n = 1.22,
with the following values for affinity and thermodynamic parameters: Ka = 1.82 × 104 ±
3.72 × 103 M-1 (Kd = 54 µM), ΔH= -12.5 ± 1.6 kcal/mol and ΔS= -22.6 cal/mol/deg. This
model yielded a goodness of fit value of ! 2 DoF = 1.06 × 105. The integrated data could
not be fitted to the ‘two sets of independent sites’ model using the Origin 7.0 software.
The best fit was obtained using the ‘sequential binding’ model for two ligands, yielding a
goodness of fit of

! 2 DoF = 5566. (Figure 42, lower panel) The affinity and

thermodynamic parameters for this model were as follows: Ka1 = 7.58 × 104 ± 8.4 × 103
M-1 (Kd1 = 12.7 µM), ΔH1= -9.5 ± 0.2 kcal/mol , ΔS1= -9.6 cal/mol/deg and Ka2 = 1.06
× 104 ± 720 M-1 (Kd2 = 94.3 µM), ΔH2= -5.6 ± 0.327 kcal/mol, ΔS2= -0.6 cal/mol/deg.
The raw data thermogram from SAH-TrmD ITC experiments was also
characterized by exothermic heats of binding. (Figure 43, top panel) The integrated heat
pulse intensities were evaluated using the same binding models discussed previously for
SAM-TrmD binding. Just as with SAM-TrmD, the integrated data for SAH-TrmD
binding could not be fitted to the “two sets of independent sites” model using the Origin
7.0 software. Fitting to the ‘single set of identical sites’ model resulted in a non-integer
stoichiometry of n = 1.28, with the following values for affinity and thermodynamic
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Figure 42. Isothermal Titration Calorimetry data measuring the energetics of SAM binding to
E. coli TrmD. The raw data peaks shown in the upper panel thermogram represent exothermic heat
pulses corresponding to 1.3 µL injections of SAM (1.6 mM) into a sample cell containing TrmD (90
µM) with an initial volume of 200 µL. Solutions were made in Tris-HCl buffer, pH 8.0. The lower
panel shows a binding isotherm of the integrated heat pulse intensities plotted against the molar ratio
of SAM : TrmD. The data was best fitted to a ‘sequential binding’ model for two ligands with Ka1 =
7.58 × 104 ± 8.4 × 103 M-1 (Kd1 = 12.7 µM), ΔH1= -9.5 ± 0.2 kcal/mol , ΔS1= -9.6 cal/mol/deg and
Ka2 = 1.06 × 104 ± 720 M-1 (Kd2 = 94.3 µM), ΔH2= -5.6 ± 0.327 kcal/mol, ΔS2= -0.6 cal/mol/deg.
ITC measurements were obtained using the MicroCal iTC200 (GE Healthcare) calorimeter and the
data was fitted using Origin 7.0 software (OriginLab® corp.)

100

Figure 43. Isothermal Titration Calorimetry data measuring the energetics of SAH binding
to E. coli TrmD. The raw data peaks shown in the upper panel thermogram represent exothermic
heat pulses corresponding to 1.3 µL injections of SAM (1.6 mM) into a sample cell containing
TrmD (72 µM) with an initial volume of 200 µL. Solutions were made in Tris-HCl buffer, pH
8.0. The lower panel shows a binding isotherm of the integrated heat pulse intensities plotted
against the molar ratio of SAH : TrmD. The data was best fitted to a ‘sequential binding’ model
for two ligands with Ka1 = 1.32 × 106 ± 8.4 × 105 M-1 (Kd1 = 0.7 µM), ΔH1= -7.3 ± 0. 321
kcal/mol, ΔS1= 3.5 cal/mol/deg and Ka2 = 8.87 × 104 ± 3.2 × 104 M-1 (Kd2 = 11.2 µM), ΔH2= 2.6 ± 0. 333 kcal/mol, ΔS2= 13.8 cal/mol/deg. ITC measurements were obtained using the
MicroCal iTC200 (GE Healthcare) calorimeter and the data was fitted using Origin 7.0 software
(OriginLab® corp.)
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parameters: Ka = 9.74 × 104 ± 1.72 × 104 M-1 (Kd = 10.2 µM), ΔH= -8.08 ± 0.39 kcal/mol
and ΔS= -4.6 cal/mol/deg. This model yielded a goodness of fit value of ! 2 DoF = 7.4 ×
104. A better fit was obtained using the ‘sequential binding’ model for two ligands,
yielding a goodness of fit of ! 2 DoF = 5.5 × 104. (Figure 43, bottom panel) The affinity
and thermodynamic parameters for this model were as follows: Ka1 = 1.32 × 106 ± 8.4 ×
105 M-1 (Kd1 = 0.7 µM), ΔH1= -7.3 ± 0. 321 kcal/mol, ΔS1= 3.5 cal/mol/deg and Ka2 =
8.87 × 104 ± 3.2 × 104 M-1 (Kd2 = 11.2 µM), ΔH2= -2.6 ± 0. 333 kcal/mol, ΔS2= 13.8
cal/mol/deg.
The raw data thermogram obtained from tRNA-TrmD ITC experiments was
characterized by endothermic heats of binding. (Figure 44, top panel) Integrated heat
pulse intensities were fitted to the ‘single set of identical sites’ model. (Figure 44, bottom
panel) A stoichiometry of n = 1.09 was obtained with the following values for affinity
and thermodynamic parameters: Ka = 2.31 × 105 ± 7.33 × 104 M-1 (Kd = 4.3 µM), ΔH= 14.4 ± 2.6 kcal/mol and ΔS= 72.9 cal/mol/deg. This model yielded a goodness of fit value
of ! 2 DoF = 1.63 × 105. The molar ratio for tRNA binding to the TrmD dimer resulted
in an integer stoichiometry of n = 1, unlike the non-integer values obtained for SAM and
SAH binding stoichiometry using the ‘single set of identical sites’ model. Fitting a tRNATrmD binding isotherm to models for multiple sites or multiple ligands did not make
sense. However, the ! 2 DoF value was rather high for the ‘single set of identical sites’
for tRNA binding so the data was fitted to a ‘sequential binding’ model for two ligands to
see if this improved (lowered) the ! 2 DoF . The following affinity and thermodynamic
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Figure 44. Isothermal Titration Calorimetry data measuring the energetics of tRNA
binding to E. coli TrmD. The raw data peaks shown in the upper panel thermogram
represent endothermic heat pulses corresponding to 2.5 µL injections of tRNA (150 µM) into
a sample cell containing TrmD (10.8 µM) with an initial volume of 200 µL. Solutions were
made in Tris-HCl buffer, pH 8.0. The lower panel shows a binding isotherm of the integrated
heat pulse intensities plotted against the molar ratio of tRNA : TrmD. The data was best fitted
to a ‘single set of identical sites’ model with N= 1.09, Ka = 2.31 × 105 ± 7.33 × 104 M-1 (Kd =
4.3 µM), ΔH= -14.4 ± 2.6 kcal/mol and ΔS= 72.9 cal/mol/deg. ITC measurements were
obtained using the MicroCal iTC200 (GE Healthcare) calorimeter and the data was fitted
using Origin 7.0 software (OriginLab® corp.).
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parameters were obtained: Ka1 = 9.63 × 104 ± 9.7 × 104 M-1 (Kd1 = 10.3 µM), ΔH1= 25.2
± 15 kcal/mol, ΔS1= 108 cal/mol/deg and Ka2 = 9.86 × 104 ± 6.5 × 104 M-1 (Kd2 = 10.1
µM), ΔH2= -13.4 ± 18.4 kcal/mol, ΔS2= -22.1 cal/mol/deg. The goodness of fit for this
binding isotherm ( ! 2 DoF = 3.54 × 105) was even higher than the ‘single set of identical
sites’ model. In addition, the standard deviation for each parameter was very high, so
taken together with the higher ! 2 DoF, it was concluded that the ‘sequential binding
model’ for two ligands was not an appropriate model for assessing tRNA-TrmD
interactions. This fitting analysis strongly suggests that TrmD does not bind two tRNA
molecules. Therefore, the ‘single set of identical sites’ model was indeed the best choice
for generating tRNA-TrmD binding isotherm parameters.
Discussion
The binding of tRNA to TrmD appears to be an entropically driven endothermic
reaction which is consistent with binding thermodynamics reported for many proteinnucleic acid interactions. The large entropy could be attributed to binding-induced release
of trapped water and ion molecules from hydrophobic pockets. The binding of SAM
appears to be an enthalpically driven exothermic reaction, while the binding of SAH
appears to be an exothermic reaction that is both enthalpically and entropically driven.
Furthermore, TrmD seems to have a higher affinity for SAH than SAM suggesting a
product inhibition mechanism. The binding of both SAM and SAH is best fitted to a
sequential binding model in which the first ligand binds with higher affinity than the
second ligand, Ka1 > Ka2. If the binding sites were identical, this would typically be
considered negative cooperativity. However, if the binding sites were initially not equally
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accessible, as was suggested by the molecular dynamics simulations of apo-TrmD, then it
becomes more difficult to determine positive or negative cooperativity. It could be that
the binding of the first ligand imposes a conformational change on the protein making a
previously non-accessible second site, now slightly more accessible, in which case, this
would be positive cooperativity. Regardless of whether the binding of SAH or SAM
occurs in a negative or positive cooperative mode, the binding data suggests that there is
cooperativity taking place. The ‘two sets of independent sites’ model could not be fitted
with the data. ITC results for SAM and SAH binding to TrmD strongly suggest that there
is communication taking place between the two sites.

4.6.2 In silico analysis of putative disulfide bonding
A candidate residue pair for cysteine mutations was identified using Disulfide by
Design as described previously. Residues A164C from the flexible linker and P58C
from the halo loop were identified as having optimal geometry (χ3 torsion angle of
+114.40) for the formation of a disulfide bond. (Figure 45) This was within the
acceptable range of χ3 torsion angles. These two residues were the only candidates
identified for linking the halo loop to the flexible linker. Residues P58 in the halo and
A164 in the flexible linker were ideal candidates for cysteine substituted mutagenesis
since they exist on opposite monomers above the active site and a disulfide bond between
them would covalently link the two monomers together.
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Figure 45. Putative disulfide bonding between residues A164C and P58C. . Residues
A164C from the flexible linker and P58C from the halo loop were identified as having
optimal geometry (χ3 torsion angle of +114.40) for the formation of a disulfhydryl bond. The
program Disulfide by Design developed by Dombkowski et al., was used to evaluate E. coli
PDB files obtained from simulation trajectories. The protein segments are modeled in ribbon
representation. The mutant residues A164C and P58C are modeled in ball and stick figures,
and SAM is modeled in faded licorice figure. The structures were generated using VMD. 114
(http://www.ks.uiuc.edu/Research/vmd
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4.6.3 A164C, P58C, and P58C-A164C mutational analysis
SDS-PAGE: A164C, P58C, and P58C-A164C
Single residue homodimeric mutants, A164C, and P58C and double residue
homodimeric mutant P58C-A164C were constructed to assess enzyme activity. The
protein migration profiles on 10% SDS-PAGE were analyzed under a variety of
experimental conditions. Initially, as per standard protocol for protein electrophoresis, the
samples were pre-heated for 5 minutes at 95 °C before prior to being loaded on the gel.
All proteins were analyzed in the presence and absence of the reducing agent DTT. The
electrophoretic pattern of A164C was identical to that of WT protein. (Figure 46) These
dimeric proteins were sufficiently linearized yielding a single size band, consistent with
monomeric molecular mass for both the oxidized and reduced samples. Proteins P58C
and P58C-A164C were also completely linearized in the presence of DTT. Surprisingly,
most of the oxidized P58C-A164C protein, which was expected to retain its dimeric
structure imposed by the hypothetical disulfhydryl bonds, also migrated as a monomer.
Only very faint bands were noted around the dimeric protein mass range. Also surprising
was that the single residue mutant, P58C, appeared to have an identical electrophoretic
migration pattern as that of the double mutant P58C-A164C. If dimerization was
occurring due to disulfide bonding in the P58C protein, it involved the engineered
cysteine in the halo, P58C, plus another cysteine possibly internal to the protein.
To address the issue of apparent low dimeric protein yield noted on the gel for the
oxidized samples P58C and P58C-A164C, SDS-PAGE was repeated as described
previously minus the pre-heating step. This was to see if, in the absence of heat, the
disulfide bonds were more stable, thus favoring the dimeric structure. Results from SDS
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Figure 46. Electrophoresis of WT E. coli TrmD and mutants P58C, A164C and P58CA164C. 10% SDS-PAGE electrophoresis gel stained with coomassie blue show TrmD
samples from WT, and P58C, A164C and P58C-A164C under oxidizing and reducing
conditions. The reducing environment was created by the addition of 2 mM DTT. Both WT
and the A164C mutant migrated as a monomer under oxidizing and reducing conditions.
P58C and P58C-A164C migrated predominantly as monomers for both oxidizing and
reducing conditions. However faint bands are seen for both in the dimeric protein mass range
under oxidizing conditions. All samples were pre-heated for 5 minutes at 95 °C before they
were loaded on the gel. The samples were electrophoresed in Tris-glycine buffer (25 mM Tris,
192 mM glycine, 0.1% SDS, pH 8.3) for 45 minutes at 150 V.
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PAGE (Figure 47) suggest that this indeed was the case. There were significantly heavier
bands noted for the oxidized P58C and P58C-A164C protein samples in the molecular
mass range consistent with dimer formation. However, there were two distinct bands
present around that range with the larger size protein band seen also in the WT and
A164C samples. This could either be due to the presence of a contaminating protein in
the prep or it could actually be TrmD dimer.

Enzyme activity: A164C, P58C, and P58C- A164C
Enzyme activity was assessed in the presence and absence of reducing agent for
WT, P58C, A164C (Figure 48) and P58C-A164C (Figure 49) proteins using the
radiolabeled enzyme assay described previously. The P58C and P58C-A164C mutants
were totally inactive in the absence of reducing agent, however, activity was completely
restored for both proteins after treatment with 2 mM DTT. The activity of A164C mutant
was comparable to WT. Furthermore, there was no change in activity after addition of
DTT for either the WT or A164C mutant. The assay results for all four proteins were
complementary to the electrophoresis data described previously. Taking these results
together, it was hypothesized that the P58C mutant protein was able to dimerize as a
result of disulfide bond formation involving the P58C in the halo loop and another
cysteine. However this does not exclude the possibility that a disulfide bond was present
between the halo and linker in the P58C-A164C mutant. To gain better insight as to the
nature of these interactions, additional mutations were performed. Rationale and results
for these mutations are discussed in the following sections.
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Figure 47. Electrophoresis of WT E. coli TrmD and mutants P58C, A164C and P58CA164C without pre-heating treatment . 10% SDS-PAGE electrophoresis gel stained with
coomassie blue show TrmD samples from WT, and P58C, A164C and P58C-A164C under
oxidizing and reducing conditions. The reducing environment was created by the addition of 2
mM DTT. The samples were not pre-heated before they were loaded on the gel. Both WT and
the A164C mutant migrated as a monomer under oxidizing and reducing conditions. P58C
and P58C-A164C mutants however, migrated predominantly as dimers under oxidizing
conditions and were sufficiently linearised after addition of DTT. The samples were
electrophoresed in Tris-glycine buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) for 45
minutes at 150 V
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Figure 48: Enzyme activity from the oxidized and reduced WT, A164C and P58C E. coli
TrmD proteins. In vitro methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-Lmethionine was used to measure TrmD activity from the oxidized and reduced WT, A164C
and P58C E. coli TrmD proteins. The reducing environment was created by the addition of 2
mM DTT. Activities from the oxidized and reduced protein samples are represented on the
graph by slanted line and checker-filled bars, respectively. Activity is reported as percent of
oxidized WT control. The P58C mutant was totally inactive in the absence of reducing agent,
however, activity was completely restored after treatment with 2mm DTT. The activity of
A164C mutant was comparable to WT. There was no change in activity after addition of DTT
for either the WT or A164C mutant. All experiments were done in duplicate. A total reaction
volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM MgCl2, 1.2 µg
BSA, 0.1 mM EDTA, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM (specific activity 10 Ci
/mMol), 20 µM tRNALeu and 500 nM E. coli TrmD. In addition, the reduced protein samples
contained 2 mM DTT.
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Figure 49. Enzyme activity from the oxidized and reduced WT, and P58C-A164C E. coli
TrmD proteins. In vitro methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-Lmethionine was used to measure TrmD activity from the oxidized and reduced WT, and
P58C-A164C E. coli TrmD proteins. The reducing environment was created by the addition
of 2 mM DTT. Activities from the oxidized and reduced protein samples are represented on
the graph by slanted line and checker-filled bars, respectively. Activity is reported as percent
of oxidized WT control. The P58C-A164C double mutant was totally inactive in the absence
of reducing agent, however, activity was completely restored after treatment with 2mm DTT.
There was no change in activity after addition of DTT WT protein. All experiments were
done in duplicate. A total reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24
mM NH4Cl, 6 mM MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 40 µM cold SAM, 1 µl (1.8 µCi)
3
H-SAM (specific activity 10 Ci /mMol), 20 µM tRNALeu and 500 nM E. coli TrmD. In
addition, the reduced protein samples contained 2 mM DTT.

112

4.6.4 Assessment of TrmD structure for internal cysteine residues
In order to investigate possible binding partners for P58C, the WT TrmD structure
was evaluated to identify cysteine residues that were native to the protein. There were
two such residues per monomer present in the protein: C112 was located on a short
segment preceding a loop comprising the SAM binding pocket and C178, located on a
segment on the carboxy side of the protein, separated from the flexible linker by a short
alpha helix. (Figure 50) The closest residue of C112 with respect to P58, is located on the
same monomer as P58 whereas the closest C178 residue is located on the opposite
monomer to that of P58. Alanine substituted mutations of these two cysteines were added
separately to the P58C-A164C mutant to see what effect this would have on dimer
formation and enzyme activity. It is important to note here that residue C112 is a
conserved residue in bacterial TrmD and previously published data from this laboratory
reveal that alanine substitutions of this residue resulted in decreased enzyme activity but
not complete inactivation. Residue C178 is not conserved in bacterial TrmD.
4.6.5 P58C- A164C-C112A, and P58C- A164C -C178A mutational analysis
SDS-PAGE: P58C- A164C-C112A, and P58C- A164C -C178A
WT TrmD and mutant proteins P58C-A164C-C112A and P58C-A164C-C178A
were analyzed on 10% SDS-PAGE in the presence and absence of DTT. (Figure 51) The
samples were not heated before being added to the gel. The oxidized P58C-A164C-178A
migrated predominantly as a heavier molecule and very little monomeric protein was
seen on the gel. After addition of DTT, most of this protein migrated as a monomer.
These results are consistent with the electrophoretic profiles of P58C and P58C-A164C
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Figure 50. Structural representations of internal cysteine residues in E. coli TrmD. The
E. coli TrmD protein possesses two internal cysteine residues, C178, located above the SAM
binding site and C112 located below the SAM binding site. The closest C112 to the P58
residue is located on the same monomer while the closet C178 residue is located on the
opposite monomer. The protein is shown in ribbon representation with the cyan and rose
coloration differentiating the two monomers. Residues C112, C178, P58 and SAM are
modeled as ball and stick figures. Residues within 5 Å of SAM are modeled as translucent
purple surface representation. The structures were generated using VMD. 114
(http://www.ks.uiuc.edu/Research/vmd)
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Figure 51. Electrophoresis of WT E. coli TrmD and mutants P58C-A164C-C178A, and
P58C-A164C-C112-A without pre-heating treatment. 10% SDS-PAGE electrophoresis gel
stained with coomassie blue show TrmD samples from WT, P58C-A164C-C178A, and P58CA164C-C112-A under oxidizing and reducing conditions. The reducing environment was
created by the addition of 2 mM DTT. The samples were not pre-heated before they were
loaded on the gel. The oxidized P58C-A164C-178A migrated predominantly as a heavier
molecule and very little monomeric protein was seen on the gel. After addition of DTT, most
of this protein migrated as a monomer. The P58C-A164C-C112A mutant migrated
predominantly as a monomer even under oxidized conditions. Virtually all of this protein
migrated as a monomer after addition of DTT. The samples were electrophoresed in Trisglycine buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) for 45 minutes at 150 V.
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described earlier. The P58C-A164C-C112A mutant migrated predominantly as a
monomer even under oxidized conditions. Virtually all of this protein migrated as a
monomer after addition of DTT.
Enzyme activity: A164C-P58C-C112A, and A164C- P58C-C178A
Enzyme activity for both P58C-A164C-C112A and P58C-A164C-C178A was lost under
oxidized conditions and was only partially regained in the P58C-A164C-C178A mutant
after addition of DTT. (Figure 52) The activity of P58C-A164C-C112A could not be
recovered even in the presence of reducing agent.
4.6.6 Discussion and conclusions of homodimeric mutational analysis
Initial experiments involving the P58C mutation suggest that under
oxidizing conditions and without heat pre-treatment, this mutant is able to maintain a
dimeric structure even after exposure to SDS denaturing solution in the sample buffer.
The fact that exposure to DTT allows this protein to migrate as a monomer on an SDSPAGE gel suggests that disulfide bonding is likely responsible for the larger sized bands
observed on the gel in the absence of DTT. There are several possibilities for disulfide
interactions involving the P58C residue that would result in retention of dimeric structure
under SDS denaturing conditions. In the P58C mutant, it is possible that a disulfide bond
is formed between P58C and the internal cysteine C178 and since the closest proximity to
this residue is located on the opposite monomer to that of P58C, a covalent bond linking
the two monomers is possible. However, it may also be possible to “lock” into a dimeric
structure even if the disulfide bonding occurred within the same monomer as would be
the case if P58C were to bond to the nearest C112 residue. Since the catalytic center is
comprised of residues from both monomers, it may be possible that a portion of the
116

Enzyme Activity
as % of oxidized WT Control

125

buffer
2 mM DTT

100
75
50
25
0
WT

P58C-A164CC178A

P58C-A164CC112A

control

Figure 52. Enzyme activity from the oxidized and reduced WT, P58C-A164C-C178A
and P58C-A164C-C112A E. coli TrmD proteins. In vitro methylation of tRNALeu,
incorporating S-[methyl-3H]-adenosyl-L-methionine was used to measure TrmD activity from
the oxidized and reduced WT, P58C-A164C-C178A and P58C-A164C-C112A E. coli TrmD
proteins. The reducing environment was created by the addition of 2 mM DTT. Activities
from the oxidized and reduced protein samples are represented on the graph by slanted line
and checker-filled bars, respectively. Activity is reported as percent of oxidized WT control.
Enzyme activity for both P58C-A164C-C112A and P58C-A164C-C178A was lost under
oxidized conditions and was only partially regained in the P58C-A164C-C178A mutant after
addition of DTT. The activity of P58C-A164C-C112A could not be recovered even in the
presence of reducing agent. All experiments were done in duplicate. A total reaction volume
of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl, 6 mM MgCl2, 1.2 µg BSA,
0.1 mM EDTA, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM (specific activity 10 Ci /mMol),
20 µM tRNALeu and 500 nM E. coli TrmD. In addition, the reduced protein samples contained
2 mM DTT.
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opposite monomer is “trapped” in an intertwined configuration as a result of this disulfide
bond. The latter scenario corroborates best with the electrophoresis data. If the two
monomers are locked in place as a result of intra-monomeric disulfide bonds, then it
would be possible to disrupt dimerization with the addition of heat. It is less likely that
this addition of heat (95 °C) would disrupt a covalent interaction resulting from intermonomeric disulfide bonding between P58C and C178. The SDS-PAGE results for
P58C-A164C-C178A and P58C-A164C-C112A mutants also support this hypothesis.
There is very little monomeric protein present on the gel for the oxidized P58C-A164CC178A mutant. Since this protein contains the C112 residue, it is possible that it
maintains a dimeric structure through intra-molecular disulfide bonding between C112
and P58C. However, the oxidized P58C-A164C-C112A mutant, containing a substituted
alanine for residue C112, migrates predominantly as a monomer although a small amount
of dimer sized protein band is also present on the gel. This could be due to a disulfide
interaction between residues P58C and C178 and/or P58C and A164C in a small fraction
of the protein population.
Results from enzyme activity assays suggest that individual cysteine substitutions
for residues A164 and P58 have no effect on enzyme function since activity is completely
restored in the P58C-A164C mutant after treatment with reducing agent. Activity results
for the P58C-A164C-C178A and P58C-A164C-C112A mutants were inconclusive since
activity could not be restored after addition of reducing agent. Although reduced activity
was expected in the mutant containing the C112A mutation, it was surprising to see
compromised activity for the C178A containing mutant since this residue is not
conserved in bacterial TrmD. It could not be deciphered solely from the assay results
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whether interactions between residue pairs P58C-A164C, P58C-C112 or P58C-C178
were responsible for the disulfide bond formation. Additional mutations will need to be
made for more conclusive interpretations. These should include P58C-A164C-C178AC112A, P58C-C178A and P58C-C112A to implicate disulfhydryl interactions between
residue pairs P58C-A164C, P58C-C112 and P58C-C178 respectively. SDS-PAGE
analysis of these mutants should give the most conclusive results rather than enzyme
activity since both P58C-A164C-C112A and P58C-A164C-C178A mutants were either
inactive or had reduced activity.
With respect to the disulfide prediction analysis performed using Disulfide by
Design, neither the C112 nor the C178 residues were implicated in forming a disulfide
bond with P58C. It is possible, given the flexibility of the halo loop, that not all
conformations are sampled by the molecular dynamics simulations. It is also possible that
the proximity of P58C to residues C112 or C178 may be different during protein
assembly and dimerization.

4.6.7

WT/WT, 00/WT, WT/D169A, WT/P58C mutational analysis
Given the results from the initial mutational analysis described above, it became

necessary to alter subsequent experiments accordingly. Although it was not conclusively
determined that P58C was interacting with C112, it was reasonably assumed to be the
case. The following proteins were constructed using the dual promoter pCDFDuet-1
plasmid: WT/WT (WT monomer with N-terminus His-tag bound to WT monomer with
C-terminus S-tag), WT/P58C (WT monomer with N-terminus his-tag bound to P58C
monomer with C-terminus S tag), WT/D169A (WT monomer with N-terminus His-tag
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bound to D169A monomer with C-terminus S-tag), and 00/WT (both monomers of this
WT dimer contain C-terminus S-tag).

Enzyme activity: WT, 00/WT, WT/WT
Enzyme assays were conducted to compare activities of three different types of
WT proteins: WT, 00/WT, and WT/WT. (Figure 53) The activity of hybrid WT/WT
protein was comparable to the original homodimeric His-tagged protein, WT. The fact
that the WT/WT contained an S-tag on one monomer and His-tag on the other did not
seem to have an effect on enzyme activity. However, the activity of the homodimeric Stagged protein, 00/WT, containing an S-tag on both monomers was substantially reduced
compared to the two other wild type proteins. Initially, attempts were made to remove the
S-tag but after several weeks without success, this strategy was abandoned. All assay
results reported here were obtained from proteins containing intact affinity tags.

Enzyme activity: WT, WT/WT, D169A, WT/D169A, P58C, WT/P58C
Activities of WT and WT/WT proteins were comparable for both the oxidized and
reduced samples. (Figure 54) The D169A mutant was completely inactive for both the
oxidized and reduced samples. Since D169 participates in catalysis, it is not surprising
that an alanine substitution of this mutation on both monomers of the dimer would yield a
completely inactive protein. The hybrid mutant WT/D169A had about half the activity of
WT in the oxidized sample and was unchanged after reducing agent. The activity of
mutant protein P58C was comparable to results described previously in that the protein
was completely inactive under oxidizing conditions and fully active in the presence of a
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Figure 53. Enzyme activity for WT, 00/WT and WT/WT E. coli TrmD. In vitro
methylation of tRNALeu, incorporating S-[methyl-3H]-adenosyl-L-methionine was used to
measure TrmD activity for three types of WT proteins differing in the nature of the affinity
tag. Activity is reported as percent of WT control. The WT/WT protein, possessing a (His)6
tag on one monomer and an S-tag on the other, had comparable activity to the WT protein
which possesses a (His)6 tag on both monomers. The 00/WT protein possessing an S-tag on
both monomers was only half as active as WT protein. All experiments were done in
duplicate. A total reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM
NH4Cl, 6 mM MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 1 mM DTT, 40 µM cold SAM, 1 µl (1.8
µCi) 3H-SAM (specific activity 10 Ci /mMol), 20 µM tRNALeu and 500 nM E. coli TrmD.
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Figure 54. Enzyme activity from the oxidized and reduced WT, WT/WT, D169A,
WT/D169A, P58C, and WT/P58C E. coli TrmD proteins. In vitro methylation of tRNALeu,
incorporating S-[methyl-3H]-adenosyl-L-methionine was used to measure TrmD activity from the
oxidized and reduced WT, WT/WT, D169A, WT/D169A, P58C, and WT/P58C E. coli TrmD
proteins. The reducing environment was created by the addition of 2 mM DTT. Activities from
the oxidized and reduced protein samples are represented on the graph by slanted line and
checker-filled bars, respectively. Activity is reported as percent of oxidized WT control. The
D169A mutant was completely inactive for both the oxidized and reduced samples. The hybrid
mutant WT/D169A had about half the activity of WT in the oxidized sample and was unchanged
after reducing agent. The activity of mutant protein P58C was completely inactive under
oxidizing conditions and fully active in the presence of a reducing agent. The hybrid protein
WT/P58C had about one fourth of the activity of wild type protein under oxidizing conditions
with activity fully restored after addition of reducing agent. All experiments were done in
duplicate. A total reaction volume of 50 µl consisted of 100 mM Tris-HCl pH 8.0, 24 mM NH4Cl,
6 mM MgCl2, 1.2 µg BSA, 0.1 mM EDTA, 40 µM cold SAM, 1 µl (1.8 µCi) 3H-SAM (specific
activity 10 Ci /mMol), 20 µM tRNALeu and 500 nM E. coli TrmD. In addition, the reduced
protein samples contained 2 mM DTT.
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reducing agent. The hybrid protein WT/P58C had about one fourth of the activity of wild
type protein under oxidizing conditions with activity fully restored after addition of
reducing agent.
4.6.8 Discussion and conclusions of heterodimeric mutational analysis
The fact that WT/D169A had only half the activity of WT suggests that both
catalytic centers are required for efficient tRNA methylation despite the fact that TrmD
binds only one RNA molecule at a time. The D169A mutation should not compromise
the structural integrity of the catalytic center of the enzyme since this residue is
responsible for deprotonation of N1G of tRNA. It therefore serves as a control for the
hybrid WT/P58C mutation which more than likely exerts a structural perturbation to one
side of the molecule. Since activity of this mutant is less than half of the WT/D169A
mutant, it suggests that structural perturbations on one side of the molecule can impede
activity on the other. If this was not the case, and the catalytic centers acted
independently from one another, then the activity for WT/P58C would be comparable to
that of WT/D169A. It is possible that a structural interdependence exists between the two
catalytic centers. This would not be surprising since the binding site for SAM is
comprised of residues from both monomers.
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5

Conclusions and Future Directions

The essential function in cellular growth and survival afforded by the m1 G37
modification in tRNA, which is found in all domains of life, has been well characterized
by our laboratory and by others. Since the bacterial methyltransferase responsible for this
modification, TrmD, bares very little sequence or structural homology to its archeal
(aTrm5) or eukaryotic (Trm5) orthologs, the prospect for selective inhibition of this
essential enzyme, makes it an attractive drug target for the development of novel
antimicrobials. However, given the ubiquitous nature of the single carbon donor SAM,
the cofactor utilized by this methyltransferase, analogs of this ligand may not be suitable
for drug development. It was therefore important to explore allosteric modes of inhibition
which required an understanding of how the enzyme functions. This involved both
computational and experimental approaches.
We have performed equilibrium molecular dynamics simulations in TIP3P
explicit solvent using the NAMD 2.7 program and CHARMM force field parameters for
both SAM-bound and apo-TrmD enzyme in order to identify changes in protein dynamics
as a result of cofactor binding. The root mean square deviations per residue for Cα atom
fluctuations during a 10 ns simulatiom implicated two highly mobile regions of the
protein, namely a halo loop and a flexible linker. These two regions, located on opposite
monomers of the homodimeric protein, form an interface above the SAM binding pocket.
We believe that the movements of the halo and linker regions above the active site
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provide a gating function allowing access to the SAM binding pocket. Further analysis
of the simulation trajectories suggested that the opening to the SAM binding site for the
SAM-bound protein alternates in a synchronized fashion between a more accessible
conformation and a less accessible conformation while the opening to the SAM binding
site for the apo-protein is much more prominent on one side of the protein compared to
the other side. The synchronized active site accessibility in the SAM-TrmD protein and
the asymmetric accessibility in the apoprotein suggests a single site mechanism for
enzyme function. This is further supported by the ITC binding studies where it was
determined that one tRNA molecule binds to one TrmD homodimer and SAM and SAH
bind in a sequential fashion.
Mutational studies using hybrid mutant proteins suggest that catalytic integrity
must be maintained in both active sites for maximum enzymatic efficiency. A mutation
on one side of the protein, impeding the flexibility of the halo loop above the active site
by an engineered disulfide bond, affected enzyme activity on the other side of the protein.
This suggests a functional interdependence between dynamic structural regions of the
protein surrounding the dual catalytic centers.
Extrinsic fluorescent dyes were used to probe the TrmD enzyme. Bis-ANS, and
congo red inhibited enzyme activity in E. coli, S. aureus and M. tuberculosis TrmD while
thioflavin T had no effect on enzyme function. Inhibition of E. coli TrmD by bis-ANS
and congo red was in the lower micromolar range with Ki values of 11.3 ± 1.7 µM and
1.3 ± 0.3 µM, respectively. Enzyme kinetics as well as fluorescent binding studies
sugguest that bis-ANS allosterically inhibits TrmD. In silico binding studies using the
GOLD docking program and HINT scoring functions show energetically favorable
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conformations of bis-ANS interculated between the flexible linker of the protein. Thus,
allosteric inhibition may result from compromised mobility of the flexible linker.
In summary, we have identified a novel “half of the sites” mechanism for TrmD
activity, previously assumed to have dual site function. We have also identified two
highly mobile regions above the active site, a flexible linker, and a halo loop which may
be gating the entrance to the deeply buried SAM binding pocket. We are suggesting that a
functional interdependence exists between these dynamic structural regions of the protein
surrounding the dual catalytic centers. An allosteric mode of inhibition for TrmD was
identified using the fluorescent dye, bis-ANS which appears to impede the mobility of the
flexible linker above the active site.
Future studies will include additional experiments to assess the allosteric mode of
inhibition for bis-ANS. Structural analogs of bis-ANS can be used to evaluate structureactivity relationship. Thirteen derivatives of bis-ANS have already been designed by Dr.
Keith Ellis, department of Medicinal Chemistry, (Figure 55) that could be used to assess
steric and electronic properties affecting ligand binding. In addition to TrmD, the
inhibitory effects should also be assessed using the mammalian ortholog, Trm5. Although
in silico studies suggest energetically favorable conformations of bound bis-ANS to
TrmD, obtaining an X-ray crystal structure of this complex would permit a more
conclusive assessment of ligand-enzyme interactions.
Computational studies could be used to identify additional inhibitors. Different
conformations of TrmD-SAM and TrmD-apo from the molecular dynamics simulations
could be used in virtual screening studies. Using the Dock 6 program developed by Irwin
Kunz at UCSF, cavity regions in close proximity to the halo and flexible linker can be
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Figure 55. Structural analogs of bis-ANS for assessment of structure-activity
relationship. Derivatives of bis-ANS designed by Dr. Keith Ellis, department of Medicinal
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determined and screened against databases of commercially available compounds. In
conclusion, the flexible linker, halo loop or the interface between these two structures
may prove to be promising targets for allosteric inhibition of TrmD enzyme.
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